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ABSTRACT 
Cancer consists of several diseases that are characterized by accumulation of genetic and 
epigenetic alterations that provide cells with certain capabilities to form tumors. Among these 
acquired capabilities are enhanced invasion that allow cancer cells to escape from the primary 
tumor, enter the circulation and eventually reach distant tissues where they form metastasis. 
Breast and prostate cancer are the most common cancers in Sweden with about 9000 new 
cases diagnosed each year. The major cause of cancer-related mortality is metastatic disease 
and new treatments interfering with the underlying mechanisms of metastasis are highly 
warranted.  
Enhanced metastasis formation has been shown to occur by reactivation of the developmental 
program epithelial-to-mesenchymal transition (EMT), regulated by various stimuli, including 
secreted factors from the tumor stroma. Cancer-associated fibroblasts (CAFs) are the most 
common stromal cell type that interacts with tumor cells to promote tumor progression and 
metastasis formation. CAFs have been identified as an important source of EMT-inducing 
factors including, among others, chemokines. CXCL14 is a CAF-secreted chemokine that 
promote tumor progression both via autocrine effects on CAFs and paracrine signaling with 
tumor cells.  
The studies in this thesis aimed to achieve a better understanding of the functions of 
fibroblast-derived CXCL14 in tumor biology and the clinical relevance of this chemokine, 
with a focus on breast and prostate cancer. The first study explored the molecular 
mechanisms underlying the protumoral effects of fibroblasts expressing CXCL14. NOS1 was 
discovered as an intracellular component of CXCL14 signaling in CAFs that maintain their 
tumor supporting functions. Enhanced oxidative stress in CXCL14-fibroblasts upregulated 
NOS1 that augmented tumor growth and tumor-infiltration of macrophages. The second 
study reports that CXCL14 expression in the tumor stroma is an independent negative maker 
for breast cancer survival. Based on sub-group specific analyses it was shown that the 
correlation between stromal CXCL14-expression and poor prognosis of breast cancer was 
more prominent in basal-like and triple negative breast cancers. Interestingly, only stromal 
expression and not tumor cell expression of CXCL14 correlated with worse survival. In the 
third study, fibroblast secreted CXCL14 was shown to promote cancer cell EMT, invasion 
and metastasis, effects directly induced by CXCL14 signaling. Moreover, ACKR2 was 
identified as a receptor for the orphan chemokine and CXCL14/ACKR2 signaling correlated 
with an EMT gene expression signature in breast cancer patients.  
In general, these studies have uncovered important functions of CXCL14 in both maintaining 
a tumor-promoting CAF-phenotype, via induction of NOS1, as well as enhancing tumor 
progression by induction of tumor cell EMT, invasion and metastasis. Furthermore, ACKR2 
was identified as a CXCL14-signaling receptor. Clinical relevance of the experimental 
findings was established by correlations of CXCL14/ACKR2 signaling with EMT and the 
identification of stromal CXCL14 expression as an independent marker for survival of breast 
cancer patients.  
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1 TUMOR PROGRESSION AND METASTASIS FORMATION 
1.1 HALLMARKS OF CANCER 
Cancer is a multistep process involving genetic alterations, including point mutations, 
deletions, amplifications and translocations, and epigenetic changes in oncogenes and tumor 
suppressor genes that affect cellular regulatory systems. These alterations drive the 
progressive transformation of normal cells into cancer cells, by providing them necessary 
capabilities for tumor development. Hanahan and Weinberg postulated six acquired 
capabilities, or hallmarks of cancer, that is shared by most human tumors: self-sufficiency in 
growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis. Together, all these 
capabilities allow cancer cells to survive, proliferate and disseminate1.  
 
Figure 1: The hallmarks of cancer. Figure modified from2. 
A few years ago, the hallmarks of cancer were revisited and extended (Figure 1). Now, 
genomic instability, re-programming of energy metabolism, tumor-induced inflammation and 
escape from immune destruction are recognized as additional hallmarks that contribute and 
foster tumor development and progression2. Interactions with the tumor stroma were also 
highlighted to contribute to the acquirement of hallmark traits. Cell types and elements of the 
tumor stroma contribute to several of the hallmarks of cancer, often by paracrine signaling 
involving secreted factors, as reviewed later. 
1.2 THE METASTATIC PROCESS  
As the primary tumor grows bigger it invades into the surrounding tissue. Tumor cells 
disseminating from the primary site enter the circulation and travel with the blood or 
lymphatic system to distant locations where they form secondary tumors, known as 
metastases. Like formation of primary tumors, the formation of metastases require the 
hallmarks of cancer described above but also additional changes, including adaptation to 
foreign microenvironments and activation of protein degradation1.  
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Metastatic disease is the major cause of cancer related mortality. By understanding the 
underlying mechanisms behind the individual steps of metastasis, formation of new 
therapeutics can be developed against metastatic disease3. A combination of intrinsic 
programs in tumor cells themselves and the involvement of the microenvironment -both in 
the primary tumor and the metastatic tissue- are essential for metastatic success. In this thesis, 
concepts for formation of metastasis, the involvement of the epithelial-to-mesenchymal 
transition (EMT) and mesenchymal-to-epithelial transition (MET) programs in each step of 
the metastatic cascade will be discussed, as well as the importance of microenvironmental 
signals for tumor cell EMT, invasion and metastasis to occur. 
1.2.1 The “seed and soil theory” for formation of metastasis   
Divergent to the hypothesis that spread of cancer cell is only dependent on the vascular 
anatomy, the “seed and soil” theory for metastatic outgrowth was described by Stephen Paget 
in the late 19th century4. According to this theory, there is a challenge for cancer cells to 
survive outside the tissue of origin and in order to form metastasis they must find a location 
with a similar microenvironment. The microenvironment in recipient organs is termed “soil” 
where tumor cells have a preference to “seed”. Thereby, tumor cells have a selectivity to form 
metastasis in the microenvironment of specific organs, a concept termed “metastatic organ 
tropism”5. For example, breast cancer mainly metastasize to bone, lung, liver and brain, 
prostate cancer to bone, colorectal cancer to liver, and gastric cancer to lung, liver and the 
esophagus6. Supporting this theory, microarray data have identified genes associated with 
organ-specific metastatic tropism and metastatic colonization of breast cancer cells to brain, 
lung, bone or liver7-10.  
This organ selectivity has been shown to involve various factors secreted from stromal cells 
including chemokines, as discussed below. Most likely, the formation of metastases is likely 
to result from a combination of the seed and soil theory, and the routes of blood and lymph 
vessels. The blood flow and lymphatic system directs the journey of the tumor cells but their 
settlement depends on a suitable microenvironment and appropriate growth conditions at the 
distant site.  
1.2.2 The different steps of metastasis  
Metastases are formed as a result of a multi-step process. A reactivation of physiological 
developmental programs is important for these steps to occur. When primary tumors 
progress, cancer cells change phenotype, become migratory and promote degradation of the 
basement membrane extracellular matrix (ECM). They invade into the surrounding tumor 
stroma and eventually into nearby tissues. This is the first step of the metastatic process, 
termed “local invasion”. During the second step, “intravasation”, tumor cells cross the 
endothelial barriers of blood- and lymph vessels and escape into the circulation. Once in the 
systemic circulation, circulating tumor cells (CTCs) need to survive before they can 
disseminate into distant organs. This third step of metastasis formation is denoted “survival in 
the circulation” or “systemic transport”. Only a few malignant cells overcome this hurdle and 
less than 0.01% of the intravasated cells have been estimated to survive in the circulation11. 
The surviving cells eventually get trapped in vascular beds and migrate through the 
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endothelium into a distant organ. This process of “extravasation” constitutes the fourth step 
of metastasis development.  During the fifth and last step of metastasis formation, “tissue 
colonization”, tumor cells encounter a foreign microenvironment. As the “seed and soil” 
theory describes, the formation of secondary tumors requires that tumor cells receive the 
proper signals to survive and grow in the microenvironment of the distant organ. Hence, only 
a subset of the cancer cells has the ability to progress and form micro-metastases that 
ultimately develop into macro-metastases6,12,13. Some malignant cells reach secondary organs 
but in the absence of triggering signals they instead enter a quiescent dormant state14.  
1.2.3 Recent aspects of metastasis formation 
In recent years, new aspects of the metastatic process have been revealed which also highlight 
the importance of the microenvironment. Among these new concepts are the “pre-metastatic 
niche” and “systemic instigation”. The pre-metastatic niche-concept further develops the seed 
and soil theory and highlights the role of the micromilieu in the establishment of metastases. 
Systemic signaling, another metastasis-related mechanism, describes one way whereby 
different cell types of the primary tumor can stimulate the outgrowth of disseminated tumor 
cells localized at distant sites15,16.  
1.2.3.1 The concept of a “pre-metastatic niche” 
The “pre metastatic niche”-model emphasizes the establishment of a niche in distant organs, 
primed by signals from the primary tumor, preceding the arrival of disseminated tumor cells 
(DTCs). The establishment of a distant organ-niche is essential to enable DTCs to form a 
secondary tumor. This is the first model suggesting the involvement of non-malignant cells in 
determining organ-specific sites for metastasis formation15,17.  
A number of studies have reported the role of bone marrow derived cells (BMDC) in 
establishing a pre-metastatic niche in lungs. Kaplan et al. showed that subcutaneous lung- or 
melanoma tumors stimulated fibronectin expression by resident fibroblast-like stromal cells 
in the lung, which created directional cues for VEGFR-1 positive BMDC and stimulated 
formation of pre-metastatic clusters. Moreover, BMDC released chemokines, such as 
CXCL12, that enhanced chemotactic migration of tumor cells expressing CXCR4, which 
supported the developing metastasis15. A more recent study demonstrated that lysyl oxidase 
(LOX), secreted from breast tumors as a result of hypoxia, is another factor involved in 
development of a pre-metastatic niche by remodeling of ECM, which promotes recruitment 
of BMDC into lung tissue18. LOX has also been demonstrated to drive the establishment of 
osteolytic bone lesions that acted as platforms, allowing circulating tumor cells (CTCs) to 
colonize the bone and form metastasis19.  
A recent published paper reported the involvement of exosomes in the formation of pre-
metastatic niches. Hoshimo et al. demonstrated that exosomal integrin-expression-patterns 
determine organotropism. Exosomes from organotropic sublines of the breast cancer cell line 
MDA-MB-231 were injected in mice prior to injection of tumor cells, with the purpose to 
educate or prime the organs. Education with exosomes from a lung metastatic subline 
enhanced the lung metastastatic capacity of a bone metastatic subline. Mass spectrometry 
identified integrins as mediators of these effects. ITG4 on lung-tropic tumor exosomes 
 4 
specifically bound fibroblasts and epithelial cells in the lung, and ITG5 on liver-tropic 
exosomes were taken up by Kupffer cells in the liver. Integrins were also shown to activate 
Src and S100 signaling that educated the target organ for outgrowth of metastasis. Clinical 
relevance of these findings was demonstrated by a correlation between high plasma levels of 
ITGA4 in breast cancer, and ITGA5 in pancreas cancer, and the subsequent development of 
lung- and liver metastasis, respectively20.  
1.2.3.2 The concept of “systemic instigation”  
Another recent concept of metastasis formation is focusing on the systemic signaling that 
occurs between primary tumors and metastases. McAllister et al. demonstrated that a primary 
tumor (“instigator”) can stimulate the outgrowth of distant, indolent tumor cells 
(“responders”) and named this process “systemic instigation”. In their study, nude mice with 
GFP-positive bone marrow served as hosts for xenograft tumors of breast cancer, and GFP-
labeled BMDC were only recruited into responding tumors in the presence of an instigating 
tumor. Osteopontin (OPN) released in the circulation was shown to be necessary for the 
recruitment and the subsequent outgrowth of indolent tumors16. It is believed that this is a 
general concept and that other tumor-derived and stromal-derived factors also are important 
for systemic instigation16. Supporting this, growth/differentiation factor 15 (GDF15) was 
recently described as the first CAF-derived factor that promotes systemic instigation, leading 
to outgrowth of indolent tumor cells21. 
1.3 EPITHELIAL-TO-MESENCHYMAL TRANSITION 
1.3.1 EMT/MET: developmental programs 
Organ development during embryogenesis is regulated by conversion of plastic cells between 
epithelial and mesenchymal states through epithelial-to-mesenchymal transition (EMT) or the 
reversible mesenchymal-to-epithelial transition (MET). The EMT/MET program is 
fundamental for different processes during embryogenesis including formation of the 
placenta, during gastrulation where the germ layers are formed, and formation of the nephron 
epithelium in the developing kidney13,22,23. 
 
Figure 2: Alteration of molecular markers during EMT. 
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Functional hallmarks of EMT are loss of cell-to-cell contact, loss of cell polarity, 
reorganization of the cytoskeleton and induction of a migrating and invading ability of the 
normally stationary epithelial cells24. The cellular and molecular changes are often induced 
by autocrine or paracrine signaling and are orchestrated by a series of transcription factors, 
including Snail, Slug, Twist, ZEB1 and ZEB2, that suppress the expression of epithelial 
markers including E-cadherin and cytokeratins and induce expression of mesenchymal 
markers including vimentin and α-smooth muscle actin (αSMA) (Figure 2).  
The biological processes of EMT and MET are re-engaged in various pathological condition 
including metastasis formation13. In tumors, induction of EMT has been shown to occur in a 
paracrine manner by secreted factors from cells of the tumor microenvironment (TME), 
including cancer-associated fibroblasts (CAFs)24,25. Among the CAF-secreted factors implied 
in EMT and metastasis formation are chemokines, further discussed in later sections.  
1.3.2 Involvement of EMT/MET in metastasis formation 
A re-initiation of the EMT program was previously demonstrated to occur during the early 
steps of metastasis formation, including local invasion of tumor cells. Nevertheless, the 
importance of EMT/MET has recently also been demonstrated during later steps, including 
distant tissue colonization23. During MET, tumor cells regain their epithelial phenotypes and 
enhanced ability to proliferate, essential for the establishment of new tumors at distant sites. 
The control of the MET program is not well understood but is believed to be regulated by the 
absence of EMT activation in combination with MET induction. Apart from the enhancement 
of tumor cell migration, invasion and metastasis, induction of EMT have been linked to 
stimulation of stem cell properties22, chemotherapy resistance26,27 and malignant 
transformation28, capabilities not further discussed in this thesis. This section will discuss 
selected studies, providing clinical and experimental evidence, of EMT/MET during the 
different steps of metastasis to define the role of EMT in the metastatic cascade. 
1.3.2.1 Local invasion 
The EMT program promotes several important key changes during the initial step of 
metastasis formation. EMT is responsible for disruption of cell-to-cell contacts, allow cancer 
cell to become more motile and enhances the degradation of ECM and basement membrane, 
processes essential for local invasion to occur. The suppression of E-cadherin has been 
described as a hallmark of EMT that results from genetic mutations or transcriptional 
inhibition29,30. 
Several experimental studies have investigated the involvement of E-cadherin loss during 
invasion and metastasis. Forced expression of E-cadherin in tumor cells and in genetic mouse 
models was shown to impair tumor cell invasion and metastasis31. In a RIP-tag model of 
pancreatic cancer that maintains E-cadherin expression, spontaneous tumor development was 
arrested at an early stage. In the same model, expression of a dominant negative mutant of E-
cadherin instead induced early invasion and metastasis32. The underlying mechanism for 
enhanced invasion and metastasis as a result of E-cadherin loss was further elucidated in a 
study by Onder et al. 2008. Knockdown of E-cadherin or expression of a dominant negative 
mutant enhanced invasion and metastasis of non-metastatic breast cancer cells by 
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upregulating EMT transcription factors and creating a feed-forward loop for EMT 
activation30.  
For efficient tissue invasion to occur, EMT also promotes degradation of the basement 
membrane and adjacent ECM by enhancing cancer cell-production of proteases. The most 
studied are the matrix metallo-proteases (MMPs) and various reports have revealed 
upregulation of distinct MMPs by the EMT transcription factors Snail and Slug33-35. In 
addition to paving the way for cancer cells, ECM breakdown also induces release of matrix 
bound growth factors, cytokines and chemokines that foster cancer cell growth, invasion and 
metastasis36,37.  
Clinical evidence for the existence of EMT during tissue invasion in human tumors has been 
confirmed in a number of studies. Loss of E-cadherin has been associated with progression of 
the disease and poor prognosis in different types of malignancies38,39. Gene expression and 
tissue analyses of human tumors have also given clinical evidence that EMT underlie the 
metastatic potency of the poor prognosis-associated claudin-low and basal subtype of breast 
cancer40,41. In basal and triple negative breast cancers, tumor cells at the invasive front were 
also shown to have undergone EMT42,43. In a study by Vincent et al, nuclear co-localization 
of Snail and SMAD3/4 was reported at the invasive front in breast carcinomas. Snail and 
SMAD3/4 formed a transcriptional repressor complex that repressed epithelial markers 
during TGFβ-induced EMT44. Similar findings have been reported in colorectal cancer where 
tumor cells at the invasive front, identified by enhanced nuclear β-catenin, displayed 
upregulated ZEB1, Snail or Twist145-47. 
1.3.2.2 Intravasation 
During intravasation, cancer cells escape through the walls of blood and lymph vessels and 
are released in the systemic circulation. The EMT program has been proposed to play an 
essential role in promoting intravasation. In PC3 prostate cancer cells, ZEB1 expression was 
shown to stimulate transendothelial migration in vitro and to enhance metastatic colonization 
in vivo 48.  
Analyses of MCF7 cells, using high-resolution imaging techniques, demonstrated the 
importance of Snail-induced membrane bound MT1-MMP and MT2-MMP for the migration 
through the vascular basement membrane34. In addition, the production of EMT-inducers as 
TGFβ from endothelial cells and the increased levels of EMT markers in CTCs, as discussed 
below, further support the hypothesis of EMT-promoted intravasation49,50.  
1.3.2.3 Transport and survival in the circulation 
In the circulation, EMT has been proposed to mediate survival of tumor cells and the 
attachment to vessel walls prior to extravasation. Circulating human and mouse tumor cells 
have been shown to display expression of EMT markers but the functional effect of EMT in 
CTCs is still poorly understood51-56. Twist1 expression in early lesions of the MMTV-Her2 
breast cancer model was associated with elevated number of DTCs in the bone marrow57. In 
concordance, Twist1 induction in an experimental model for squamous cell carcinoma and 
Snail and Slug expression in a breast xenograft model both enhanced the number of tumor 
  7 
cells in the circulation. The CTCs displayed an EMT phenotype and the increase was 
associated with enhanced metastasis52,58.  
One suggested reason for the maintenance of an EMT phenotype in CTCs is the prevention of 
anoikis, detachment-induced cell death. Loss of E-cadherin in breast tumor cells has been 
reported to enhance metastasis through induced anoikis30,59. As endothelial cells, platelets 
have been identified as a source for TGFβ-production that might retain the CTCs in an EMT 
state. A study by Labelle et al. 2011 showed that CTCs associate with platelets and specific 
inhibition of platelet-derived TGFβ reduced the number of distant metastasis in experimental 
mice models60. In line with these experimental data, CTCs in breast cancer patients have been 
reported to associate with platelets and to upregulate the TGFβ-pathway51. 
Additional clinical evidence for the involvement of EMT during survival of CTCs comes 
from observation of EMT-phenotypes in human CTCs. In colorectal cancer, CTCs exhibited 
EMT phenotypes and the number of CTCs was associated with worse survival61. In 
hepatocellular carcinoma patients, similar findings were demonstrated and the levels of Snail 
in CTCs were elevated in patients with metastasis55.  
1.3.2.4 Extravasation 
The involvement of EMT during extravasation is not well understood and the reason is 
mainly lack of relevant model systems. The establishment of an extravasation assay in 
zebrafish, that allow real time imaging of human tumor cells in the circulation, has shed some 
light on EMT-induced extravasation.  In a study by Stoletov et al., forced expression of 
Twist1 in breast cancer cells was shown to enhance tumor cell extravasation in the zebrafish 
model. In addition, upregulation of Twist1 also promoted formation of membrane protrusions 
that enhanced extravasation, essential for and metastasis formation to occur62. 
Interaction with stromal cells has also been reported to affect extravasation. As mentioned 
earlier, TGFβ signaling from endothelial cells and platelets activated tumor cell EMT that 
might promote extravasation50,60.  
1.3.2.5 Survival in a new microenvironment and tissue colonization 
The relevance of EMT for metastasis formation has been questioned due to the lack of 
mesenchymal tumor cells present in metastatic lesions. At least two different proposals have 
been made to explain this phenomenon. Firstly, it has been suggested that mesenchymal and 
epithelial cancer cells cooperate to complete the full metastatic process. EMT cells may lead 
the way for invasion and intravasation of non-EMT cells that eventually form the 
metastastatic tumor49,63. Tsuji 2008 demonstrated, by inoculation of mixed labeled 
mesenchymal and epithelial tumor cells in mice, that mesenchymal cells showed enhanced 
invasion and intravasation but only the epithelial cells formed the secondary tumors. A 
second alternative is implying a reversion of the EMT program (or activation of the MET 
program) during colonization of the new tissue. This is supported by findings that, following 
tail vein injection of the mesenchymal breast cancer cell line MDA-MB-231, re-expression of 
E-cadherin was detected in the resulting metastatic lesions64.  
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When tumor cells reach secondary organs as the final destination of the metastatic journey, 
enhanced motility is no longer needed. For tissue colonization to occur, tumor cells instead 
need to re-initiate proliferation, which has been turned off during the previous steps of 
metastasis. There is compelling evidence from the literature that proliferation of a cell depend 
on microenvironmental cues different from those that promote migration, and induction of 
EMT have been shown to repress cell division and proliferation52,65-67.  
If the absence of EMT-inducing factors in the new microenvironment is sufficient for an 
EMT reversion or if cancer cells need additional MET inducers is not fully known. 
Experimental studies have indicated both. Withdrawal of Twist1 activation in DTCs of a skin 
tumor model enhanced formation of macro-metastasis, indicating that absence of EMT can 
promote metastasis establishment52. In line with these results, loss of the EMT inducer Prrx1 
was required for the reversion of EMT in lung tissue, allowing colonization and formation of 
secondary tumors68. The importance of MET-inducing signals has also been shown in the 
MMTV-PyMT model of spontaneous breast cancer. In this model, bone marrow derived 
myeloid cells in the metastatic niche of lungs promoted breast cancer cell MET, proliferation 
and lung colonization by production of versican69. The activation of fibroblasts in the lung-
niche by metastatic mesenchymal tumor cells has also been reported to induce MET and 
subsequent tissue colonization, described in detail in the section about CAFs70. 
In summary, this reversible EMT model thus implies that tumor cells can convert between 
mesenchymal and epithelial states, similar to what occur during embryonic development as 
discussed above, to be able to adapt to the changing microenvironment both in the primary 
and metastatic tumor. 
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2 THE TUMOR MICROENVIRONMENT  
Solid tumors are highly heterogenic and composed of several cell types, including cancer 
cells, endothelial cells, pericytes, various immune cells and cancer-associated fibroblasts 
(CAFs). There is a tight interplay between stromal and malignant cells, which contribute to 
cancer initiation, growth, and metastasis, and targeting opportunities within the tumor stroma 
are continually being identified25,71. In addition, the microenvironment in metastatic tissues 
has recently been reported to play a major role in the establishment of secondary tumors. This 
section will describe the cells and molecules that form the tumor microenvironment, with 
relevant examples of studies exploring the function of the primary and metastatic tumor 
microenvironment in promoting cancer progression, EMT/MET and metastasis. Cancer-
associated fibroblasts will instead be separately discussed in chapter 3. 
2.1 CELL TYPES AND COMPONENTS IN THE TUMOR MICROENVIRONMENT  
2.1.1 Extracellular matrix  
Extracellular matrix (ECM) is composed of different molecules that surround the cells in the 
tumor. These include collagen, fibronectin, hyaluronan, laminin, elastin and proteoglycans, 
which provide support and anchorage for the adjacent cells and sequester various growth 
factors. In tumors, degradation of ECM is a requirement for tumor growth and tissue invasion 
that further promote the release of factors essential for progression and metastasis72.  
Increased matrix stiffness has previously been associated with tumor progression but how the 
mechanical forces promote the progression of cancer has been elusive73-76. In a study by Wei 
at al, enhanced matrix stiffness was linked to the activation of an EMT response, invasion and 
metastasis by enhanced nuclear localization of the EMT transcription factor Twist77. An 
increase in stromal collagen deposition has also been shown to correlate with advanced 
malignancy and metastasis in colorectal cancer and breast cancer, respectively78,79. Zhang et 
al. identified the collagen receptor DDR2 to sustain EMT by stabilization of Snail, which 
promoted migration, invasion and formation of breast cancer metastasis79. Furthermore, 
hypoxia-induced LOX-expression in primary tumors was shown to enhance ECM remodeling 
and increase tumor cell invasion and formation of breast cancer metastasis80. One alternative 
mechanism for induction of LOX is transcriptional activation by the ECM component 
hyaluronan that promoted breast cancer cell EMT, invasion and metastasis by upregulation of 
twist81. 
LOX has also been shown to be a significant player in the formation of a pre-metastatic niche 
as mentioned earlier18,19. By cross-linking of collagen fibers at distant sites LOX signaling 
attracted BMDC secreting MMP2. BMDC-MMP2 signaling in lungs enhanced ECM 
degradation and created a feed-forward loop for BMDC recruitment that established a 
suitable niche for tumor cells to form metastasis in18. The establishment of pre-metastatic 
niches has also been shown to depend on other matrix components, including Fibronectin15, 
Versican69, periostin (POSTN) and tenascin-C. POSTN and tenascin-C where produced by 
stromal cells at the metastatic site and activated Wnt and Notch-signaling in cancer cells to 
facilitate the outgrowth of tumor initiating cells in the lung82-84. Together, these studies 
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highlight the importance of the ECM composition in determining outgrowth of tumor cells at 
metastatic sites. 
A tumor protective effect of the ECM was recently reported in a study on naked mole rats. 
The naked mole rats are rodents that live underground with an unusual longevity and 
resistance to tumor development. This study uncovered that secretion of a specific heavy 
hyaloronan (HA) from fibroblasts was sufficient to make the naked mole rat resist 
development of cancer. Knock down of HAS2, the enzyme that synthetizes HA, or 
overexpression of the HA-degrading enzyme HYAL2 made naked mole rat cells susceptible 
to malignant transformation85. 
2.1.2 Endothelial cells 
Tumor angiogenesis is an essential process for tumor growth and metastasis. Progression of 
tumors is dependent on oxygen and nutrients. As tumors grow, hypoxia and nutrient 
deprivation tilts the balance between pro- and anti-angiogenic factors that trigger the 
“angiogenic switch”, a transition from an avascularized hyperplasia to a vascularized 
outgrowing tumor86,87. The production of pro-angiogenic factors induce formation of new 
blood vessels in tumors that exhibit irregular shape and are leaky, compared to normal blood 
vessels. The most studied angiogenic factor is vascular endothelial growth factor (VEGF). 
Blood vessel formation is induced when VEGF binds to its receptors on endothelial cells and 
enhances sprouting and proliferation. VEGF inhibitors are in clinical use for treatment of 
several cancers88,89. In addition to foster tumor growth, the ingrowth of blood vessels also 
promotes metastatic spread of cancer cells to distant organs87. However, anti-angiogenic 
treatment of tumors have, in some model systems, been shown to promote invasiveness and 
development of metastasis90,91. In this section, the function of endothelial cells specifically 
during metastatic spread will be reviewed through summaries of selected studies. 
Tumor cell-endothelial cell interactions in the primary tumor and at the metastatic site have 
recently been investigated for the importance of metastasis formation. The involvement of 
endothelial hypoxia inducible factor (HIF)-signaling for metastatic success was explored in 
mouse models with an endothelial-specific deletion of HIF1-α or HIF2-α. Loss of HIF1-α 
signaling in endothelial cells was shown to impede metastasis formation. Injection of GFP 
labeled Lewis lung carcinoma cells in these models demonstrated that the reduction of 
metastasis could be linked to impaired intravasation, evident by a reduction of GFP positive 
cells in the circulation. However, loss of endothelial HIF2-α was instead shown to enhance 
tumor cell metastasis, demonstrating how endothelial cells can have different impact on 
metastasis formation92. The role of the chemokine signaling during extravasation and 
metastasis formation of colon cancer was explored by Wolf et al. In this study, CCL2 
secreted by tumor cells activated CCR2 and downstream JAK2-Stat5 and p38MAPK 
signaling in endothelial cells to promote vascular permeability and metastasis formation93. 
The role of the endothelium in regulating breast tumor cell dormancy was also recently 
explored in in vivo models. At breast cancer metastatic sites of brain, lung and bone, dormant 
tumor cells were shown to reside in the microvasculature. The endothelium constituted a 
dormant niche that kept cancer cells in a quiescent state through trombospondin-1 signaling. 
Remodeling of the vasculature and endothelial cell sprouting reduced trombospondin-1 and 
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induced Periostin and TGF-β1 expression that reverted the tumor suppressing function of the 
endothelium, which allowed outgrowth of micrometastasis94. VEGFR+ endothelial progenitor 
cells from the bone marrow have also previously been shown to participate in the formation 
of the pre-metastatic niche, dictating organ specific metastasis15.  
The formation of lymphatic vessels in tumor tissue is believed to occur in parallel with blood 
vessels, a process called lymphangiogenesis95, where family members of the VEGF-family 
play a significant role96,97. These vessels consist of specialized endothelial cells -sparsely 
covered by smooth muscle cells and pericytes- and represents a route for metastatic spread. 
The number of lymph vessels in tumors has also been shown to correlate with lymph 
metastasis and poor prognosis in several types of cancers98-101. 
2.1.3 Pericytes  
Pericytes are perivascular cells surrounding the blood vessels where they support the vascular 
wall, regulate blood flow, mediate vessel maturation and remodeling, as well as vascular 
permeability via paracrine signaling with the endothelium102,103. The role of pericytes in 
cancer is not fully characterized. Some studies have demonstrated that increased pericyte 
coverage on tumor blood vessels was associated with enhanced tumor growth104,105. Others 
have shown that a reduction of pericyte coverage resulted in an enhanced formation of 
metastasis106,107 and correlated with poor clinical outcome108-111. 
It was previously unclear if pericytes actively participated in formation of metastasis or if 
they only represented a physical barrier to prevent extravasation. One recent study explored 
the functional role of pericytes in cancer progression and metastasis. By using genetic mouse 
models and pharmacological inhibitors to deplete or inhibit NG2+ and PDGFβR+ pericytes, 
authors concluded that these cells promote growth of primary tumors but suppress metastasis. 
The increase in metastasis formation in these mice was explained by an increase in hypoxia, 
activation of EMT and elevated Met expression in cancer cells. Silencing of Twist or 
treatment with a Met inhibitor reduced the hypoxic response and the number of metastasis106. 
Different subpopulations of pericytes have been identified based on marker expression and 
PDGFβR-expressing pericytes was identified as a progenitor cells for different subsets112-114. 
However, the function of individual pericyte-populations in tumor biology is poorly explored. 
A recent study showed that a subpopulation of PDGFβR expressing perivascular cells in 
patients with serous ovarian cancer was correlated with worse survival115, in line with the 
growth promoting effects of PDGFβR pericytes demonstrated by earlier studies104,106. The 
impact of PDGF-signaling on pericyte-regulation and metastasis development was analyzed 
in a study by Hosaka et al. In tumors with high levels of PDGF-BB, targeting of the PDGF-
pathway inhibited tumor growth and metastasis by preventing detachment of pericytes. In 
contrast, targeting of tumors with low PDGF-BB ablated vessel-associated pericytes and 
augmented tumor growth and metastasis116. In concordance, several studies have 
demonstrated that inhibition of PDGF-signaling promoted pericyte detachment and enhanced 
sensitivity to anti-angiogenic treatment117-119. 
Another study by Keskin et al. further explored the roles of tumor pericytes. The study 
showed that depletion of pericytes during early breast tumor progression reduced metastasis, 
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whereas pericyte depletion at later stages of tumor progression was associated with enhanced 
primary tumor hypoxia and increased metastasis formation. Pericyte-endothelial cell 
interactions involving angiopoietin-2 signaling were responsible for the increase in breast 
tumor metastasis, and authors suggested targeting of both pericytes and angiopoietin-2 
signaling for treatment of metastatic breast cancer120. 
2.1.4 Platelets 
In the circulation, cancer cells must survive various stresses including matrix detachment, the 
interaction with immune cells and the hemodynamic shear forces. Shielding of CTCs with 
platelets has been shown to be an efficient strategy to avoid immune recognition, resist the 
mechanical forces of the circulation and facilitate tumor cell arrest and adhesion to the 
endothelium11,121. By creating a shield, platelets elicit pro-metastastatic functions. However, 
emerging evidence has also revealed a more complex interplay between platelets and various 
cell types in the circulation that primes tumor cells for metastasis. Here, a few studies are 
given as examples of platelet function during the formation of metastasis. 
Platelet-tumor cell interaction was shown to enhance tumor metastasis by stimulating EMT, 
as described previously60. Another study by the same authors demonstrated that platelets can 
guide the formation of an early metastatic niche by paracrine signaling between tumor cells 
platelets and granulocytes. According to this study, CXCL5/7 chemokine production by 
tumor cell-activated platelets recruits CXCR2-positive granulocytes to metastatic tissues to 
form a microenvironment favorable for metastatic seeding122. Moreover, Schumacher et al. 
reported that tumor cell-stimulated ATP secretion from platelets activated P2Y2 receptors on 
endothelial cells and enhanced transendothelial migration of cancer cells. Abrogation of P2Y2 
receptors on endothelial cells or the inhibition of ATP release from platelets in mice 
prevented tumor cell extravasation and subsequent formation of metastasis123. In a mice 
model of melanoma, the pro-metastatic functions of platelets were shown to be organ specific 
and platelet-interactions specifically increased lung metastasis124. Therapies interfering with 
platelet function, as long-term treatment with aspirin, have shown success in reducing risk of 
metastatic disease, which further supports a metastasis-promoting role of platelets125. 
2.1.5 Immune cells 
Macrophages, lymphocytes, natural killer (NK) cells, mast cells, granulocytes, neutrophils 
and eosinophils are immune cells that are present in the inflammatory microenvironment of 
tumors. Cytotoxic T-cells and NK cells have been shown to target and suppress tumor cells, 
and infiltration of these immune cells in tumors is associated with a favorable prognosis in 
several tumor types126. During recent years strategies to enhance these cytotoxic responses for 
the treatment of cancer patients have given promising results. Adoptive cell therapy and the 
use of monoclonal antibodies against immune checkpoint inhibitors, including CTLA4 and 
PD1-PDL1, are examples of such strategies127,128.  
On the other hand, mast cells, granulocytes, immature myeloid cells, neutrophils and 
macrophages are immune cells involved in enhancement of tumor progression, associated 
with poor prognosis of several cancers11,129-132.  
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The following section will discuss a selection of concept-forming literature on two immune 
cells; macrophages, major producers of chemokines that have been extensively studied for 
their tumor promoting activities, and neutrophils that recently was reported as major players 
during tumor metastasis formation by creating a pre-metastatic niche. 
2.1.5.1 Macrophages 
Macrophages are involved in several oncogenic processes and have the ability to initiate 
tumor formation, stimulate angiogenesis, promote tumor growth, invasion and metastasis, 
remodel tissues and regulate immune responses133,134. However, the involvement of 
macrophages in cancer biology is somewhat contradictory. A high infiltration of 
macrophages has been linked to poor prognosis in several malignancies such as breast, 
prostate, lung, skin cancer and lymphoma135-140. On the contrary, a high intra-tumoral number 
of macrophages in colon cancer have been associated with a better outcome141,142. The 
explanation for this is a polarization into a “classically activated” tumor inhibitory M1 
population, and an “alternatively activated” tumor stimulatory M2 population133,143.  
Various chemokines, such as CCL2, CCL5, CCL7, CCL15, CXCL12 and cytokines 
including colony stimulating factor-1 (CSF-1), PDGF, VEGF and IL-10, are highly involved 
in the recruitment of macrophages into primary tumors and metastasis134,144-147. Previous 
studies have suggested that tumor-infiltrated macrophages have a phenotype similar to 
M2133,148. However, recent studies have demonstrated that tumor associated macrophages 
(TAMs) exhibit a phenotype different from M2, indicating that differentiation of TAMs from 
monocytes occur through a distinct pathway149. In line with these findings, a recent study also 
revealed that transcriptional activation of macrophages resulted in a spectrum of activation 
states beyond the M1/M2 phenotypes150. 
The roles of macrophages in tumor cell EMT, invasion and metastasis have been 
demonstrated by several studies144. Some of these studies are here presented as examples. Lin 
et al showed that silencing of CSF-1 in MMTV-PyMT mice reduced infiltration of 
macrophages in mammary tumors, which further decreased the formation of pulmonary 
metastases151. Another study revealed the importance of primary tumor-macrophages, via 
induction of MMP-9 and VEGF, in metastatic colonization in lung of tail-vein-injected tumor 
cells152. DeNardo et al. reported that T-lymphocytes present in breast tumors in MMTV-
PyMT mice secreted IL-4 to activate EGF signaling by TAMs. Ligand-activated EGFRs on 
breast cancer cells stimulated invasiveness, entry to the lung and establishment of 
metastasis153.  
Macrophage derived factors including chemokines, TGFβ, NFκB, Wnt5a and IL-10 have 
been shown to induce EMT154. A feed-forward loop between macrophages and tumor cells 
through GM-CSF-CCL18 signaling was demonstrated to activate EMT, invasion and 
metastasis formation, which is further discussed in the chemokine section155. Enhanced 
CXCL12/CXCR4 and CXCL5/CXCR2 signaling in breast cancer mediated infiltration of 
GR-1+CD11+ myeloid cells that enhanced invasion and metastasis through upregulation of 
MMPs and TGFβ156. Gao et al. reported that primary tumors of PyMT mice showed an 
increase in TAMs that created an EMT-promoting microenvironment by production of 
TGFβ, EGF and PDGF. On the contrary, in the metastatic lesions there were fewer TAMs 
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and enhanced number of bone marrow derived myeloid cells that instead induced MET by 
production of the proteoglycan versican69. 
The importance of macrophages in metastatic tumors has just recently been explored. 
Macrophage-secretion of granulin in liver metastasis of a mouse model of pancreatic ductal 
carcinoma (PDAC) promoted the shift of hepatic stellate cells into periostin-producing 
myofibroblasts, which sustained the growth of metastatic tumor cells. Inhibition of 
macrophage recruitment or granulin secretion reduced stellate cell activation and lowered the 
metastatic burden157. Chemokine-expression in metastatic tissues have also been reported 
enhance the entry of macrophages. In a mouse model of invasive colorectal cancer, cancer 
cells secreting CCL9 and CCL15 stimulated chemotaxis of CCR1 positive immature myeloid 
cells to the liver and enhanced formation of liver metastasis146. Another chemokine, CCL2 
was shown in a study by Qian et al to correlate with breast cancer metastasis and outcome. 
The mechanism was explained by CCL2 expression by the target organ stroma and metastatic 
tumor cells that enhanced recruitment of a subpopulation of inflammatory CCR2-positive 
monocytes. These monocytes efficiently promoted extravasation and metastatic seeding. By 
blocking CCL2-CCR2 signaling, metastasis formation was reduced and survival of tumor 
bearing mice were prolonged147. 
2.1.5.2 Neutrophils 
Neutrophils have during recent years been shown to foster tumor metastasis by mechanisms 
involving establishment of a pre-metastatic niche, enhanced EMT, tumor cell migration and 
invasion, facilitating extravasation and immunosuppression158. Some recent papers discuss 
the specific involvement of neutrophils at the metastatic site, with different effects on 
metastasis formation. 
Wculek et al showed a recruitment of neutrophils to the lung parenchyma before entry of 
metastatic tumor cells. Neutrophil production of leukotrienes specifically expanded a 
subpopulation of tumor initiating breast cancer cells, which eventually formed lung 
metastasis. Depletion of neutrophils or inhibition of leukotriene production reduced the 
number of metastasis formed in the MMTV-PyMT breast cancer model and abrogated the 
pro-metastatic function of neutrophils159. Coeffelt et al. reported a cross talk between 
mammary tumor cells, γδT-cells and neutrophils involving an IL-1β/IL-17/G-CSF signaling 
cascade. This cascade promoted systemic expansion and polarization of neutrophils that 
enhanced distant metastasis in experimental models by suppression of CD8 cytotoxic T-
cells160. 
As other stromal cells, neutrophils have also been associated with tumor-restraining effects. 
In the same breast tumor models used as in previously mentioned studies tumor entrained 
neutrophils (TENs) was shown to have anti-metastatic functions. Consistent with the studies 
above, TENs arrived to lungs prior to the entry of metastatic tumor cells but was shown to 
have cytotoxic effects by production of H2O2, enhanced by cancer cell-derived CCL2. 
However, the suppressive functions of these neutrophils were eventually outcompeted by the 
tumor cells and micro-metastases were formed161. 
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3 CANCER-ASSOCIATED FIBROBLASTS  
CAFs constitute a major part of many solid tumors and are the most abundant cell type within 
the tumor stroma, where they are involved in tumor initiation, growth and formation of 
metastasis. In addition, they display both prognostic significance of different tumors and 
targeting opportunities25. Functions of CAFs, not described here in detail are; support for 
stem cells162, immune modulatory effects163, metabolic interaction with tumor cells164,165 
modulation of drug sensitivity. This section will -with relevant examples of studies- focus on 
the involvement of CAF-phenotypes in tumor progression and the local and systemic pro-
metastatic signaling in both primary tumors and at metastatic sites.  
3.1 PHENOTYPES AND ORIGIN OF CAFS 
Tumors have been described as wounds that never heal. The tumor stroma is similar to the 
stroma during fibrosis or wound healing, characterized by an elevated number of fibroblasts, 
increased capillary density and changes in the ECM166. As tumors progress, there is a co-
evolvement of the tumor stroma, and fibroblasts exhibit an activated state, similar to 
fibroblasts associated with wound healing167. CAFs display a specific myofibroblast 
phenotype, are active in ECM turnover and show increased proliferation as compared to 
normal fibroblasts. Unlike cancer cells, CAFs are not considered to display major genetic 
aberrations25,71.  
Differences in the expression of cell surface markers suggest the existence of several CAF-
subpopulations and it is likely that CAFs in different cancers display functional variations. 
Markers expressed by CAFs include α smooth-muscle actin (αSMA), fibroblast specific 
protein (FSP-1), platelet-derived growth factor receptor α and β (PDGFRα and PDGFRβ), 
fibroblast-activating protein (FAP) and vimentin71,168.  
The occurrence of CAF-subsets can possibly be explained by diverse origins. CAFs have in 
general been considered to arrive from local fibroblasts stimulated by various growth 
factors166. Experimental studies have provided some additional clues and they might be 
derived from bone marrow-derived precursors169-172, arise from normal and malignant 
epithelial cells that have undergone EMT or from endothelial to mesenchymal transition173-
177. Pericytes expressing αSMA have been suggested as an additional origin for CAFs102. In 
line with this, a recent study identified a population of activated myofibroblasts during injury, 
derived from perivascular cells178.  
Emerging multi-marker studies have recently explored the existence of CAF-subsets. A study 
by Sugimoto et al. could for the first time describe two distinct subsets of CAFs, from models 
of breast and pancreas cancer. One was defined by expression of αSMA, PDGFRβ and NG2 
and the other by expression of FSP1179. 
3.1.1 Transcriptional programs determining CAF-phenotypes 
Until recently, very little has been known about the transcription factors that determine CAF-
phenotypes. Susan Lindquist laboratory could identify the ubiquitously expressed 
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transcription factor heat shock factor 1 (HSF1) as an important modulator of reprogramming 
of resident fibroblast into activated CAFs, which enhanced tumor progression by activating 
expression of TGFβ and CXCL12. The activation resulted in enhanced angiogenesis, ECM 
remodeling and increased tumor cell adhesion and migration. The study further demonstrated 
that stromal expression of HSF1 in lung and breast cancer significantly correlated with worse 
patient survival180. 
Stromal expression of EMT transcription factors have also lately been shown to alter the 
CAF-phenotype. Stromal Snail levels was linked to poor prognosis of breast and colon cancer 
through mechanisms involving augmented ECM stiffness that supported tumor metastasis 
and altered cytokine production181. Another EMT transcription factor, Twist, was described 
to be involved in activation of CAFs in colorectal cancer and gastric cancer. Twist expressing 
CAFs induced pro-invasive and pro-tumorigenic effects by increased matrix stiffness and 
production of secreted factors182,183. A study by Sung et al. also showed that Twist1 
expression in CAFs was associated with enhanced lymph node metastasis and poor survival 
of gastric cancer patients184. Yet another EMT transcription factor, ZEB1 was demonstrated 
to distinguish CAFs and normal fibroblasts in prostate cancer185. 
In addition, regulation of other signaling networks have been shown to reprogram CAFs. A 
transcriptional regulator of hedgehog signaling, FOXF1, was shown to induce a CAF-
phenotype significant for progression of non-small cell lung carcinoma186 and the YAP 
transcription factor was required for CAF-functions, such as matrix stiffening, invasion and 
angiogenesis187. The vitamin D receptor (VDR) expressed in the tumor stroma of human 
pancreas cancer was shown to act as a master transcriptional regulator of stromal remodeling, 
suppressing pancreatic stellate cells (PSC) upon activation with the VDR ligand calcipotriol. 
The suppression of PSC affected their ability to support tumor growth and a combination of 
calcipotriol and gemcitabine treatment significantly reduced tumor volume and enhanced 
survival of treated mice, compared to chemotherapy alone188. 
Epigenetic alteration has also recently been described to enforce conversion of fibroblasts 
into pro-invasive CAFs, via activation of LIF-signaling. LIF activated an epigenetic switch 
that enhanced the JAK1/STAT3 pathway and an invasive behavior of tumor cells189. 
3.1.2 Good versus bad fibroblasts in cancer 
In vitro experiments of co-cultured normal fibroblasts and cancer cells have previously 
revealed anti-growth stimulating effects of fibroblasts190-192. Lately, also CAFs with tumor 
restrictive functions have been identified in in vivo models of cancer193-195  
Rhim et al. published that epithelial deletion of Sonic hedgehog (Shh) or pharmacological 
inhibition of its signaling mediator Smoothened in a mouse model of PDAC reduced the 
stroma content and enhanced tumor growth, angiogenesis and metastasis193. A similar finding 
that the stromal response to Shh mediates tumor restriction was made in a study on bladder 
cancer. Stromal deletion of smoothened in mice with chemically induced bladder cancer 
accelerated tumor initiation, increased proliferation, gave undifferentiated tumors with 
decreased BMP signaling and reduced mice survival. Activation of BMP signaling prior to 
formation of invasive carcinoma was able to impede tumor progression by inducing 
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differentiation of tumor cells194. In early and late stage of pancreas cancer, myofibroblasts 
and fibrosis was also shown to protect against tumor progression, by immune-modulatory 
effects. Depletion of αSMA-positive fibroblasts reduced survival of tumor bearing mice. 
Depleted tumors were undifferentiated, showed enhanced EMT and stem cell characteristics. 
Tumors also displayed an increase in regulatory T-cells but a decrease in infiltration of other 
immune cells, suggesting that fibroblast restrain tumor progression by enhancing the immune 
response to control pancreas cancer195.  
3.2 TUMOR PROMOTING EFFECTS OF CAFS 
In cancer, CAFs are important for tumor initiation, growth and metastasis196-199. Among the 
pro-tumorigenic factors derived from CAFs are for example growth factors that stimulate 
proliferation and help to evade apoptosis, factors that induce angiogenesis, factors modulating 
drug sensitivity and chemokines, mediating various effects on different cell types (Figure 
3)25.  
  
Figure 3: The effects of CAF-signaling on the tumor microenvironment. 
Figure adapted from25. 
3.2.1 Tumor initiation and growth 
CAFs in different tumors produce a variety of factors, including, TGFβ, hepatocyte growth 
factor (HGF), fibroblast growth factor (FGF), IL-6 and the chemokine CXCL12, that have 
been shown to induce cellular transformation196. A direct tumor initiating capacity of CAFs 
was shown by a fibroblast specific knock down of the TGFβ type II receptor. The inability of 
a fibroblast TGFβ response led to spontaneous development of cancer in prostate and the 
forestomach, and tumor progression through enhanced paracrine HGF-c-Met signaling 
between fibroblasts and tumor cells200.  
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Several other experimental studies relying on co-injection of tumor cells and fibroblasts in 
immunosuppressed mice have also demonstrated the importance of this cell type for tumor 
initiation, growth and progression. Some tumor cells only form tumors in mice in the 
presence of fibroblasts and different fibroblast also vary in their ability to promote tumor 
growth201,202. A study by Erez et al. identified a pro-inflammatory gene signature in CAFs 
important for their tumor promoting activities, including tumor growth. Co-injection of skin 
carcinoma cells with CAFs in mice resulted in fast-growing tumors, compared to co-injection 
with normal fibroblasts. Inhibition of the NFκB signaling pathway revealed its involvement 
in regulating the pro-inflammatory CAF-phenotype and enhanced tumor growth203. 
Fibroblasts secrete a number of growth factors that enhance tumor cell growth and survival. 
Epidermal growth factor (EGF), HGF and TGFβ are involved in the sustained tumor cell 
proliferation, and insulin-like growth factors (IGFs) are involved tumor cell survival25,166. 
CAF-derived factors that stimulate tumor growth also include chemokines, such as CXCL12 
and CXCL14 that will be extensively discussed later on. 
3.2.2 Tumor angiogenesis  
The formation of new blood vessels in tumors -as a result of CAF-signaling- has been shown 
by direct VEGF-secretion or by induction of other pro-angiogenic factors71. These factors 
include among others, FGFs, CXCL12 and CXCL14197,204,205. CXCL12 and CXCL14 are two 
CAF-derived chemokines that recruit bone marrow-derived endothelial precursor cells or 
immune cells into growing tumors197,205. Fibroblast-derived CXCL14 was highly upregulated 
in human prostate CAFs and autocrine CXCL14 signaling enhanced angiogenesis through 
FGF-2 production205. Moreover, tumors exhibited increased prostate tumor growth and 
content of macrophages. The specific role of CAF-produced chemokines will further be 
discussed in the section about CAFs and chemokines.  
3.2.3 EMT, invasion and metastasis 
The involvement of CAFs in EMT, invasion and metastasis has been extensively explored. In 
this section a selection of papers will be discussed that demonstrate conceptual findings 
regarding local effects of CAFs in the primary tumor, systemically acting CAF-secreted 
factors and effects of CAFs at metastatic sites. 
3.2.3.1 Local effects in the primary tumor  
Direct pro-metastatic effects of CAFs in the primary tumor, including effects on EMT, 
invasion and hypoxia have been shown in several studies.  
A pro-metastatic program activated by TGFβ signaling in CAFs was identified in colorectal 
cancer. TGFβ induced CAF-secretion of IL-11 that bound GP30 on cancer cells and activated 
STAT3 signaling, promoting the initiation and survival of metastatic cancer cells in the 
liver206. Another CAF-produced factor involved in metastasis of colorectal cancer is the 
glycoprotein Stanniocalcin 1 (STC1). PDFGRβ signaling was responsible for enhanced 
expression of STC1 in fibroblasts that increased migration and invasion of cancer cells in 
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vitro. Mice with tumors containing STC1-/- mouse embryonic fibroblasts (MEFs) displayed 
less metastasis as a consequence of reduced EMT and intravasation207. Karnoub et al. also 
demonstrated that mesenchymal stem cell (MSC) altered metastasis formation through 
chemokine-induced EMT of breast cancer cells, and the interaction of tumor cells with MSC 
was required to maintain the metastatic phenotype199. The pro-EMT and metastatic effects of 
chemokines produced by CAFs will be discussed in detail in a later section. 
Hypoxia has also been shown to affect CAFs in primary tumors. A fibroblast-specific knock 
down of HIF-1α in a murine mammary tumor model was shown to accelerate tumor 
growth208. In another study by Madsen et al., deactivation of CAFs was mediated by chronic 
hypoxia that inhibited PHD2 activity, which prevented HIF1-α degradation and enhanced 
levels of αSMA and periostin. Pharmacological inhibition or genetic deletion of PHD 
decreased CAF-activation in vivo, diminished matrix stiffness and lowered the number of 
distant metastasis in a breast tumor model209. These data demonstrate how the hypoxic 
response in the tumor microenvironment can impair tumor aggressiveness by reversion of the 
CAF phenotype. A study published at the same time reported strikingly similar findings. 
CAFs isolated from PHD2 haplodeficient PyMT mice showed less activation, impared matrix 
remodeling and reduced ability to promote invasion and metastasis. A specific 
haplodeficency of PHD2 in CAFs did however not affect the metastatic ability, and authors 
instead demonstrated that the above effects was mediated by impaired TGF-β1 signaling 
from PHD2 deficient tumor cells210. Together, these two studies imply that targeting of PHD2 
in breast cancer patients could prevent metastatic disease, by affecting both cancer cells and 
the TME.  
3.2.3.2 Systemic effects from the primary tumor and formation of a pre-metastatic-niche 
In a recent study, CAFs was demonstrated as a previously unrecognized source of systemic 
instigation. GDF15 -a member of the TGFβ family- was upregulated in human prostate tumor 
stroma compared to normal prostate stroma and enhanced levels was shown in the circulation 
of GDF15-tumor bearing mice21 and in prostate cancer patients211. Forced expression of 
GDF15 in fibroblasts promoted prostate xenograft tumor growth and, more importantly, 
enhanced the outgrowth of indolent prostate cancer cells at a distant site in a mouse model for 
systemic instigation21. This is the first study demonstrating a role of the tumor stroma in 
enhancing metastatic potential by systemic effects. 
Pro metastatic factors that have been shown to contribute to the formation of a pre-metastatic 
niche include members of the VEGF family15, OPN16, and LOX18. CAFs have been shown to 
be an important source of these factors that may act systemically to affect the growth of 
tumor cells at distant sites71.  
3.2.3.3 Local effects in the metastatic niche 
The importance of CAF-produced factors in the primary tumor and the metastatic niche, 
determining metastatic organotropism, was uncovered by the Massagué group. In this study, 
the abundance of CAFs in triple negative breast cancer patients was linked to the specific 
establishment of bone metastasis. How these organotropic metastatic traits arose in primary 
tumors was investigated by analysis of a CAF-gene expression signature from these patients. 
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CXCL12, IGF-1, CXCL14 and IGF-2 were identified as potential mediators. Experimental 
data showed that CXCL12 and IGF-1 secreted from CAFs selected tumor cell clones with 
high Src activity. This selection enhanced the ability of these clones to adapt and survive in 
the bone marrow -rich in CXCL12 and IGF-1- and eventually to form bone metastasis212. 
Malanchi et al. also demonstrated the importance of CAF-paracrine signaling at the 
metastatic site. Tumor cells entering the lung interacted with fibroblasts and activated their 
production of POSTN to initiate tissue colonization83. A recent study also demonstrated that 
POSTN-producing CAFs activated by macrophages in the liver were involved in promoting 
establishment of liver metastasis, as mentioned earlier157. An additional study demonstrated 
that the EMT/MET program is a key regulator of stromal niche activation at the metastatic 
site, which enhanced tissue colonization. The mesenchymal phenotype of cancer cells -
characterized by AXL expression and EMT markers- and their secretion of thrombospondin-
2 were important for activation of fibroblasts in the metastatic tissue. Activated fibroblasts 
reverted tumor cells from a mesenchymal phenotype to an epithelial phenotype, mediated by 
inhibition of TGFβ-signaling and induction of BMP-signaling70. 
In summary, CAFs produce a variety of factors that enhance tumor cell invasion and 
metastasis through an interplay with other cell types in the primary and metastatic tumor, as 
well as via systemic signaling. In addition, CAFs are also producers of ECM components and 
matrix remodeling enzymes that increase tumor stiffness and enhance tumor progression and 
metastasis formation discussed earlier18,74,187. Furthermore, CAFs have also been shown to 
guide cancer cells during invasion, creating paths where tumor cells follow213. 
3.3 CLINICAL RELEVANCE AND TARGETING OF CAFS 
3.3.1 Prognostic significance of CAFs 
The prognostic significance of single CAF-markers, CAF-derived factors and CAF-gene 
expression signatures has been demonstrated in a number of studies. A selection of these 
studies is provided here to exemplify the impact of CAFs on cancer patient outcome.  
In breast cancer, stromal marker expression of PDGFRβ, αSMA, TGFβR2 and Gli1 have 
been identified in various studies to negatively associate with survival214. CAF-produced 
factors correlating with worse breast cancer outcome also include the ECM components 
hyaluronan and tenascin-C215,216. On the contrary, the enhanced levels of FAP in breast tumor 
stroma was linked to increased disease-free and overall survival217. There are also conflicting 
data from different studies on the impact of certain markers for breast cancer prognosis, 
which suggest that more extensive research is needed to validate theses as prognostic CAF-
markers, and also for the identification of new stromal prognostic markers in breast cancer. 
These include stromal expression of podoplanin and CAV1218-222. 
Calon et al. discovered that genes previously identified to associate with poor prognosis 
subgroups of colorectal cancer were enhanced in the tumor stroma compartment compared to 
the epithelial compartment. Purification of individual cell types from CRC-specimen revealed 
CAFs as the cell type predominately expressing these poor prognosis genes. Expression of 
CAF-genes was further analyzed and demonstrated to identify poor-prognosis patients in the 
good-prognosis subtypes. Stromal expression of the three genes CALD-1, FAP and IGFBP7 
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were upregulated by TGFβ-signaling and correlated significantly with shorter disease-free 
survival in colorectal cancer patients. FAP and IGFBP7 also displayed epithelial expression. 
Notably, the epithelial expression of FAP and IGFBP7 was not associated with colorectal 
cancer prognosis. Experimental data showed that TGFβ-signaling in CAFs enhanced the 
tumor initiating capacity of CRC cells inhibition of TGFβ prevented formation of metastasis 
in mice223. 
Beside the studies on the prognostic role of single CAF-markers and secreted factors, stromal 
gene expression signatures have recently been explored and shown to correlate with patient 
survival223-225. The evidence for stromal prognostic markers and gene expression signatures 
also suggest that tumor stroma-characteristics are candidate targets for cancer therapy.  
3.3.2 Targeting of CAFs 
The tumor stroma has been shown to influence the therapeutic outcome of cancer patients, as 
well as provide opportunities for targeting. CAFs are likely more genetically stable than 
cancer cells and thus not as prone to develop resistance to treatment. CAFs can either be 
targeted by interfering with the pro-tumorigenic secreted factors or by interfering with the 
recruitment or expansion of CAFs. Considering the importance of growth factors in CAF 
signaling, as discussed previously, targeting of the recruitment or expansion of CAFs involve 
inhibition of growth factor signaling. Tyrosine kinase inhibitors, such as Imatinib, 
Sorafinitinib and Sunitinib that have anti- PDGF receptor targeting activity are used in the 
clinic for treatment of several malignancies25,71. The involvement of chemokines in tumor 
promoting fuctions of CAFs also suggests these molecules as potential targets. 
However, the recent discovery of tumor protective CAF-subsets make targeting of CAFs 
more complex. Identification of molecular mediators that specifically mediate tumor 
promoting or tumor restraining effects is therefore prompted. 
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4 CHEMOKINES  
4.1 CHEMOKINES AND CHEMOKINE RECEPTORS  
More than 50 chemokines and approximately 20 chemokine receptors make up the 
chemokine circuit. The large number of chemokines compared to chemokine receptors gives 
a redundancy within the chemokine signaling network and one chemokine ligand can bind 
multiple receptors. One receptor can also interact with more than one chemokine 226-228. Yet, 
some chemokine receptors only recognize a specific chemokine, for example CXCR4 that 
only binds CXCL12226. Chemokine-ligands are classified based on function, including 
inflammatory or homeostatic roles, or based on structural motifs. Classical chemokine 
receptors are named according to which structural ligand-subclass they bind. An alternative 
class of chemokine receptors does also exist as will be described below. 
4.1.1 Classification of chemokines  
4.1.1.1 Inflammatory and homeostatic chemokines 
Chemokines are divided based on functional properties into inflammatory or homeostatic 
chemokines. Inflammatory chemokines, as for example CCL2, CCL5 and CXCL8, are 
upregulated upon inflammation and are involved in recruitment of immune cells to the site of 
inflammation. On the contrary, homeostatic chemokines including CXCL12 have a 
constitutive lymphoid organ- or tissue expression and they mediate homing of cells under 
normal conditions. However, the inflammatory and homeostatic functions are not mutually 
exclusive and some inflammatory chemokines may have homeostatic roles, and vice versa227.  
4.1.1.2 Structural motifs 
The typical chemokine structure involves four highly conserved cysteine residues connected 
by disulfide bonds. The position of the first two N-terminal-cysteine residues make up the 
basis for chemokine systematic nomenclature and classification into the four subclasses CXC, 
CC, CX3C and (X)C227,228. The N-terminus of chemokines is important for inducing receptor 
signaling, but is not critical for high affinity receptor binding229. 
4.1.2 Classification of chemokine receptors 
4.1.2.1 Classical chemokine receptors 
Chemokine receptors are divided into four classes, named according to the ligand with which 
they interact. For example, CC chemokines binds CC receptors and CXC chemokines binds 
CXC receptors. An atypical chemokine receptor class has also been described with distinct 
functions227,228,230. 
4.1.2.2 Atypical chemokine receptors 
The atypical chemokine receptor (ACKR)-subfamily is composed of four receptors 
designated ACKR1-4. ACKRs are defined as scavenging receptors based on the ability to 
bind chemokines with high affinity, without activating classical chemokine signaling. They 
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were therefore excluded from the systematic nomenclature. Two more receptors, CCRL2 and 
PITPNM3, are under investigation and might in the future be classified as ACKR5 and 6231-
233.  
4.2 CHEMOKINE SIGNALING 
4.2.1 Classical chemokine signaling 
Chemotactic cytokines or, in short, chemokines are a family of proteins secreted by various 
cell types upon stimulation with inflammatory cytokines, growth factors or pathogenic 
stimuli. They are involved in several processes, including inflammation, lymphoid organ 
development, wound healing and cancer, where they influence different aspects of cell 
behavior, such as cell migration and growth226,234. Chemokines are key players in the immune 
defense against foreign pathogens. One of the best-studied functions is the directed migration 
of leukocytes toward an increasing chemokine gradient, a process called chemotaxis. Cells 
expressing the appropriate chemokine receptor will travel toward a high local concentration 
of the ligand, where they become activated226,235. 
The biological effects of chemokines are mediated by binding to seven-transmembrane-
domain G-protein coupled receptors (GPCRs)229,236. GPCR-signaling is orchestrated by 
receptor-associated G-proteins consisting of three subunits; α, β and γ. Upon ligand binding, a 
conformational change in the receptor enables the substitution of GDP to GTP in the Gα 
subunit, followed by its dissociation from the G-protein complex. Both the Gα and the Gβγ 
subunits are released and activates intracellular signaling events237. Chemokine receptors 
belong to the Gαi-subfamily of GPCRs and are sensitive to a toxin produced by the bacteria 
Bordetella Pertussis. Pertussis toxin (PTX) catalyzes ADP-ribosylation of the Gαi-subunit, 
which prevents GTP binding and subsequent dissociation and activation of downstream 
signaling, such as calcium influx, chemotaxis and mitogen-activated protein kinase (MAPK) 
pathway (Figure 4)238-240.   
 
Figure 4: Intracellular pathways activated by chemokine signaling. 
Figure adapted from241.  
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4.2.2 Signaling of ACKRs 
The structural-functional relationships of chemokine receptors are not completely known but 
certain sequence motifs have been proposed to affect downstream signaling. ACKRs do not 
all lack the same conserved signature motif that could explain the inability to activate G-
protein signaling242, but modification of the DRYLAIVHA motif has been assumed to 
explain the inability of atypical chemokine receptors to induce receptor signaling after 
chemokine interaction243. Notably, versions of this signature motif exist within classical 
chemokine receptors, and the insertion of the DRYLAIVHA motif in ACKR3 did not 
activate downstream signaling244.  
Recent evidence does also support classical signaling functions for members of the ACKR-
family. ACKR3 was demonstrated to bind PTX sensitive Gαi-proteins and to activate 
CXCL12-dependent calcium mobilization, ERK- and AKT signaling in rodent astrocytes and 
human glioma cell lines. Furthermore ACKR3-CXCL12 signaling in these cell types 
enhanced their migration and proliferation245,246.  
ACKR2, earlier designated D6 or CCBP2, is an atypical chemokine receptor highly 
expressed on lymphatic endothelial cells in the skin, gut and lungs, trophoblasts in the 
placenta247,248, on macrophages and astrocytes in the brain249,250. ACKR2 is mapped to the 
chemokine receptor cluster on the chromosomal region 3p21, with a DKYLEIVHA version, 
instead of a DRYLAIVHA motif251. The ability to induce calcium mobilization after ligand 
binding was originally identified for murine ACKR2 by overexpression of the receptor in 
HEK293 cells251. Human ACKR2 did however fail to activate calcium mobilization and 
chemotaxis in response to the ligand CCL2. Instead, CCL2 interaction mediated receptor 
internalization and ligand degradation252.  
The inability of ACKRs to induce calcium mobilization or chemotaxis after interaction with 
certain ligands can be explained by different reasons. ACKRs might have a sequestering 
function for some chemokines and instead induce signaling for others. ACKRs might also 
signal via other mechanisms. Recent evidence for a novel β-arrestin-mediated signaling 
function of ACKR2 was reported in a study by Borroni et al.253. 
4.3 CHEMOKINES IN TUMOR PROGRESSION 
In tumors, chemokines and their corresponding receptors have an abundant expression and 
are produced by tumor cells and stromal cells including leukocytes, endothelial cells and 
CAFs. They are responsible for the recruitment of various cell types and have been shown to 
affect tumor growth, angiogenesis, invasion and metastasis226,254-256. Nevertheless, the 
function of chemokines varies among malignancies and they can display either tumor-
inhibitory or tumor-promoting roles226. In the following sections certain chemokines will be 
given as examples on how chemokines are involved in tumor biology. 
4.3.1 Immune infiltration in tumors 
CCL2 and CCL5 are two chemokines that can induce macrophage migration into tumors with 
subsequent production of macrophage-derived factors that stimulate cancer cell proliferation, 
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angiogenesis and invasion (discussed in the section about macrophages). In breast cancer and 
colorectal cancer patients, high levels of CCL5 and CCL2 was correlated with the number of 
infiltrated macrophages, with an unfavorable prognosis and with lymph node metastasis257-
260. In tumor models of melanoma, low levels of CCL2 have instead been correlated to an 
increase of M2 macrophages, blood vessel formation and tumor growth261. Correspondingly, 
the survival rate was higher in pancreatic cancer patients with high levels of circulating 
CCL2, compared to patients with low levels262. These results reflect the contradictory 
functions of one chemokine in different tumors and the complexity of chemokine signaling.  
Other chemokines that contribute to the infiltration of leukocytes in tumors, and with direct 
pro-angiogenic functions include CXCL8, CXCL1-3 and CXCL5254,263. 
4.3.2 Tumor growth and angiogenesis 
Direct effects on proliferation and survival of tumor cells have been shown for chemokines in 
various cancers. CXCL12 have been shown to stimulate cell proliferation and migration 
through CXCR4 and ACKR3 (earlier CXCR7)264-266 and a high CXCR4 expression has been 
clinically associated with poor prognosis in different tumors226. Moreover, CXCL12 has been 
shown to promote angiogenesis by recruitment of endothelial cell precursors that further 
facilitates tumor growth and progression197. Macrophage-secretion of CXCL8 that interacts 
with CXCR2 on endothelial cells also induced angiogenesis267. Similar findings of CXCL8-
promoted angiogenesis related growth and metastasis in mouse models of melanoma and 
pancreas cancer have also been reported268,269.  
4.3.3 EMT/MET program and metastasis formation 
Activation of cancer cell EMT occurs by secreted factors from tumor cells themselves and 
cells of the tumor stroma25,172. Chemokines are example of such EMT-inducing factors as 
mentioned before. Two aspects of chemokine signaling have been shown to regulate 
metastasis formation; 1. Local chemokine-crosstalk between stromal cells and tumor cells in 
the primary tumor that enhance EMT, migration, invasion and subsequently 
metastasis155,199,212,270, 2. Systemic effects of chemokines expressed in distant tissues that 
determine metastatic tropism of tumors cells expressing the corresponding receptors255,271,272. 
The effects of chemokines and chemokine receptors on EMT, invasion and metastasis have 
been extensively analyzed in experimental cancer models and in human tumors. A few 
selected studies are discussed below to illustrate modes and mechanisms whereby 
chemokines influence EMT/MET and metastasis. 
4.3.3.1 Pro-metastatic effects of chemokines in the primary tumor 
Breast tumor cells that have undergone EMT was shown to secrete GM-CSF to activate 
TAMs. TAM-production of the chemokine CCL18 enhanced EMT and a GM-CSF-CCL18 
feed-forward loop was formed that increased breast tumor metastasis in mice. Moreover, 
GM-CSF-CCL18 signaling was associated with worse prognosis in breast cancer patients155. 
The chemokine receptor CXCR4 was also demonstrated to enhance breast tumor cell EMT 
and formation of lymph node metastasis in mice273. In a study by Visciano et al. tumor cell-
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activated mast cells stimulated EMT and stemness-features in thyroid cancer by activation of 
a CXCL8-Akt-Slug pathway274. In lung cancer cells, CXCR4 and ACKR3 were the most 
upregulated chemokine receptors by TGFβ. ShRNA-mediated knockdown of the atypical 
receptor ACKR3, but not CXCR4, reverted TGFβ-induced EMT migration and invasion275. 
A recent study provided further insights of the function of atypical chemokine receptors in 
vivo. ACKR4 (earlier designated CCX-CKR) did not appear to scavenge chemokines in a 
xenograft model of breast cancer. ACKR4-overexpressing xenograft tumors had no alteration 
of the ligands compared to control tumors. Instead, the receptor was shown to enhance breast 
cancer metastasis, via multiple mechanisms that included enhanced motility, EMT and 
resistance to anoikis276. 
A recent study revealed a molecular link between metastasis and chemo-resistance that 
involved CXCL1/2 paracrine signaling between tumor cells, myeloid cells and endothelial 
cells. CXCL1/2 promoted infiltration of myeloid cell into mammary tumors that expressed 
S100A8/9. S100A8/9 enhanced formation of lung metastasis and further supported survival 
of cancer cells. Treatment with chemotherapy induced TNFα-production by endothelial cells 
that enhanced CXCL1/2 expression in cancer cells, which amplified the paracrine CXCL1/2 
signaling and caused chemo-resistance. Alteration of this paracrine crosstalk via CXCL1 
inhibition increased the efficacy of chemotherapy270.  
4.3.3.2 Pro-metastatic effects of chemokines in the metastatic niche 
Chemokines affect tumor progression not just only in the primary tumor site by enhancement 
of tumor cell growth, angiogenesis, migration and invasion. Also, it has been shown that 
chemokine expression at metastatic sites will determine the site of metastasis formation. The 
concept that cancer cells with a certain chemokine receptor will “home” to tissues and organs 
expressing the chemokine ligand, thereby directing metastatic destination, has been proven 
for several chemokine receptors. Breast cancer cells was shown express the chemokine 
receptor CXCR4, which made them home to the bone marrow, lung and liver, tissues where 
CXCL12 is expressed255,277. This concept of chemokine and chemokine receptor involvement 
in metastasis tropism was confirmed in a B16 mouse melanoma model. By overexpression of 
chemokine receptors in cancer cells the site of metastases could be controlled. CCR10 was 
shown to be involved in skin metastasis278, CCR7 gave lymph node metastasis279 and CXCR4 
caused lung metastasis280. 
Massagué and colleagues could explain how cancer cells survive at distant sites by studying 
the involvement of chemokines in latent bone metastasis formation from primary breast 
cancers. In cancer patients, metastasis can occur after several years suggesting a dormant 
state of tumor cells. In this study CXCL12 was shown to be involved in the survival of 
dormant breast cancer cells in the bone marrow, which contributed to the metastasis 
latency281. As discussed earlier, CXCL12 derived from BMDC has also been shown to be 
important for establishment of a pre-metastatic niche in lung15. 
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4.3.4 Prognostic relevance of chemokine-signaling 
A number have studies have reported on the association of chemokine and/or chemokine 
receptor expression with patient outcome in different cancers. Worse survival of pancreatic 
cancer was significantly associated with high CXCL5 expression282 and hepatocellular 
carcinoma with high CXCR6 expression283. In a study exploring CXCL12 expression in 
gastric cancer authors identified an upregulation in CAFs compared to normal fibroblasts. 
Immunohistochemistry (IHC) analysis of human tumor tissue-material showed expression of 
CXCL12 in αSMA positive stromal cells and an association of high CXCL12 expression and 
poor outcome. However, no data was shown for the specific correlation of stromal CXCL12 
expression and patient survival284. 
4.3.5 Targeting of chemokine-signaling 
Small-molecule receptor antagonists inhibit chemokine signaling by interacting with the TM-
helices of the receptor. There are two small-molecule chemokine receptor inhibitors on the 
markets, approved for clinical use. AMD3100 targeting CXCR4 is used for stem cell 
mobilization, and Maraviroc blocking CCR5 are used for treatment of HIV-1. There are 
currently no monoclonal antibodies available for use in a clinical setting. However, ongoing 
clinical trials are promising for treatment of various malignancies. An inhibitor of CCR2 was 
tested in phase 2 clinical trials for treatment of bone metastases, but was suspended. A CCR4 
inhibitor is tested in ongoing phase 1 and 2 clinical trials, either alone or in combination with 
chemotherapy, for T-cell and NK-cell lymphomas. CXCR4 receptor antagonists are currently 
in phase 1 clinical trials for treatment of acute myeloid leukemia 285. 
4.4 CHEMOKINES AND CANCER ASSOCIATED FIBROBLASTS  
As discussed previously in this thesis, the establishment of primary tumors and metastasis is a 
complex process dependent on the interaction between the malignant cells and the 
microenvironment. CAFs and chemokines can act independently to promote cancer growth 
and metastasis, but there is also paracrine chemokine signaling between tumor cells and 
stromal fibroblasts that enhance tumor progression. In this section, examples of relevant 
studies will be discussed and a selection of certain chemokines has therefore been made.  
4.4.1 Tumor growth and angiogenesis 
The research of pro-tumorigenic chemokines produced by CAFs has mainly been focused on 
CXCL12. The direct effect on tumor cells, such as enhanced proliferation, migration and 
invasion, mediated via CXCR4 have been shown for several malignancies, including breast-, 
prostate-, oral- and pancreatic cancer 197,269,284,286-289. CXCL12 was early shown to be elevated 
in breast CAFs compared to normal fibroblasts, taken from noncancerous region of the same 
breast, and was shown to increase growth and blood vessel infiltration of breast tumors in 
vivo by interacting with CXCR4 on malignant cells respectively on endothelial cells197. The 
growth of tumors and angiogenesis was inhibited by treatment with CXCL12 neutralizing 
antibodies197. Furthermore, resident fibroblasts have been shown to engage CXCL12 
autocrine signaling to promote the conversion into protumoral CAFs290.  
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Primary CAFs was also shown to secrete CCL2 that stimulated breast cancer stem cell 
characteristics through upregulation of NOTCH1. An inducible CCL2 knock down in 
primary CAFs was obtained by treatment with doxycycline-induced shRNA against CCL2. 
Treated CAFs were co-implanted with breast cancer cells orthotopically and administration 
of doxycycline specifically decreased CCL2 levels, accompanied by decreased NOTCH1 
expression and delayed and reduced tumor forming capacity, suggesting that CCL2 is 
important for fostering the cancer stem cell population in breast cancer291.  
4.4.2 EMT, invasion and metastasis 
Chemokines produced by CAFs have also been demonstrated to display pro-EMT, -invasive 
and -metastatic activities. 
In a study by Jung et al. the importance of chemokine signaling for recruitment and activation 
of CAFs, that further augmented tumor cell EMT and distant metastasis, was reported. In 
primary prostate tumors, expression of CXCL16 was shown to enhance CXCR6-positive 
MSC-recruitment and to promote the differentiation into CAFs, based on CAF-marker 
expression and tumor promoting ability. These CAFs secreted CXCL12 that induced EMT 
and facilitated dissemination of tumor cells. Knock down of CXCL16 in tumor cells was 
shown to decrease tumor growth in vivo and revert MSC infiltration and CAF conversion292. 
In addition to the involvement of stromal CXCL12 in metastatic organ tropism that was 
described earlier212, a role for CXCL12/CXCR4 signaling in enhancing breast cancer 
metastasis was shown in a study by Smith et al. Inhibition of CXCR4 with RNAi, or the 
antagonist AMD3100, decreased proliferation and/or survival of malignant cells, and 
substantially delayed metastatic growth in mice293.  
A study by Qian et al. showed that CCL2 is highly involved in promoting breast cancer 
metastasis. CCL2 expression both by the lung stroma and by metastatic tumor cells is 
essential for recruitment of CCR2 positive macrophages, which enhanced extravasation of 
tumor cell into lung tissue and promoted metastatic seeding147. The involvement of CCL5 in 
metastasis formation has also been demonstrated. GFP-labeled breast cancer cell lines were 
subcutaneously co-implanted with bone marrow-derived human MSCs in immune-
compromised mice. MSCs expressed CCL5 as a response to paracrine stimulation by tumor 
cells. By interacting with the corresponding receptor CCR5 on breast cancer cells, CCL5 
enhanced motility and invasion that further promoted formation of pulmonary metastasis. 
Inhibition of breast cancer cell CCR5 with shRNA or neutralizing antibodies was sufficient to 
abrogate MSC-induced metastasis199.  
Together, these studies emphasize the importance of chemokines, produced by CAFs, in 
affecting both tumor cells and the microenvironment to facilitate tumor growth and 
metastasis formation. The role of another CAF-derived chemokine, CXCL14 will be 
discussed in detail in the following section. 
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5 CXCL14, A PARACRINE PROMOTER OF TUMOR GROWTH   
5.1 BIOLOGICAL FUNCTIONS OF CXCL14 
CXCL14, also designated BRAK, MIC-1, MIP-2γ or KS1, is a 77 amino acid small protein 
that belongs to the CXC chemokine subfamily. The chemokine is highly conserved between 
humans, mouse, birds, frog and fish294,295. In humans, CXCL14 is expressed in barrier tissues 
such as skin, lungs, small intestine, placenta, kidney and brain296-298. The chemokine is highly 
expressed in epithelial cells, but keratinocytes and dermal fibroblasts in the skin, trophoblasts 
in the placenta and microglia in the brain do all express CXCL14299. CXCL14 displays a 
broad chemotactic activity, as demonstrated for e.g. immature dendritic cells (iDC), 
monocytes, macrophages, NK-cells and B-cells, but not T-cells298,300-303. However, studies on 
CXCL14 knock out mice have not revealed any alteration in the number of macrophages and 
dendritic cells (DCs) in the skin, compared to CXCL14 wild type mice. Furthermore, 
CXCL14 transgenic mice did not display alterations in lymphocytes, macrophages and 
DCs299. 
Various studies on the biological functions of CXCL14 have identified CXCL14 as a 
pleiotropic chemokine, involved in immune cell trafficking, glucose metabolism and insulin 
resistance, neurological functions regulating feeding behavior and neurotransmission, 
antimicrobial activities and embryonic development299. 
One function of CXCL14 expression in barrier tissues, such as the skin, is antimicrobial 
effects against certain skin bacteria. Antimicrobial activities are important to avoid extensive 
growth of microorganisms in constantly exposed tissues. Normally in the skin, this is 
mediated by specific antimicrobial peptides (AMP) including defencins and cathelicidin LL-
37. These peptides mainly mediate receptor-independent effects, but some have also been 
shown to interact with chemokine receptors. Interestingly, CXCL14 share similar structural 
motifs as these AMPs and some of CXCL14 functions could thus potentially be receptor-
independent304.  
The mechanistic regulation of CXCL14 functions is poorly understood, mainly due to the 
lack of a known receptor for the chemokine. Identification of a CXCL14-receptor would 
increase the understanding of the normal biological functions of CXCL14, but also the role(s) 
of CXCL14 in tumor biology. 
5.2 CXCL14 IN CANCER 
The expression of CXCL14 is absent in many cancer cell lines and lost in epithelial cells of 
several tumors296,297,305,306. Nevertheless, some tumors show increased expression of CXCL14 
in the tumor compartment307,308 or in the tumor microenvironment205,277,297,301, compared to 
normal tissue. The functional role of CXCL14 in various cancers has been addressed in 
previous reports. Some of them indicate a tumor suppressive function, whereas other instead 
point to a tumor promoting role of CXCL14299.  
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5.2.1 Tumor-suppressive functions of CXCL14 
The downregulation of CXCL14 in malignant cells in certain cancers have been shown as a 
result of epigenetic silencing of the CXCL14 gene305,309,310. In lung cancer patients, the 
CXCL14 gene promoter is commonly methylated, consistent with enhanced promoter 
methylation of CXCL14 in lung cancer cell lines. To investigate the effect of CXCL14 
silencing during tumor progression, CXCL14 was re-expressed in lung cancer cells. Forced 
expression reduced tumor growth in vivo and enhanced tumor necrosis. In vitro data showed 
a decrease in cell proliferation, increased cell death and interestingly, enhanced cell migration 
of lung cancer cells305.  
Moreover, studies analyzing the effects of CXCL14 over-expression in cancer cells have 
reported both anti-tumoral effects through inhibition of cell proliferation in breast cancer 311, 
and by regulation of immune cells302,312. Overexpression of CXCL14 in a highly metastatic 
subclone of MDA-MB-231 cells reduced proliferation and invasive properties in vitro, and 
attenuated growth of orthotopic xenograft tumors and pulmonary metastasis formation in 
vivo311.  
Since CXCL14 is a chemoattractant for various immune cells, the epigenetic silencing of the 
gene in malignant cells could be one way of tumors to escape immune recognition. This 
notion was supported from studies on CXCL14 transgenic mice where chemically induced 
colorectal cancer was suppressed via a reduction in NK-cell mediated immune 
surveillance313. 
Chemokines can be classified by the ability to induce angiogenesis based on the presence or 
absence of an ELR motif 314. Most of the CXC chemokines are ELR+ angiogenic factors, with 
the exception of CXCL12. CXCL12 induces formation of new blood vessels although the 
chemokine lacks the ELR motif, by effects on VEGF signaling197,315. Anti-angiogenic effects 
of cancer cell- or host-derived CXCL14 have been revealed in animal models of lung cancer, 
melanoma and head and neck cancer301,316. Shellenberger et al. demonstrated that CXCL14 
inhibited endothelial cell migration and thereby caused a decrease in angiogenesis, using a rat 
corneal micropocket assay. This study also detected CXCL14 in stromal fibroblasts next to 
tumor cells in patients with human squamous cell carcinoma of the tongue. Functional 
significance of the stromal expression was not analyzed in this study301. 
5.2.2 Protumoral effects of CXCL14 
Protumoral effects of CXCL14 have also been identified. In prostate cancer Schwarze et al. 
showed enhanced CXCL14 mRNA expression in stromal fibroblasts compared to tumor cells, 
and stromal levels increased with prostate cancer stage307. Also in human prostate and breast 
cancer, CXCL14 expression was up-regulated in CAFs as compared to normal fibroblsts. As 
detailed below, the protumoral effects of CXCL14 include increased cell proliferation, 
invasiveness and stimulation of tumor growth and metastasis.  
Tissue culture and mouse cancer model-studies of breast and prostate cancer demonstrated 
protumoral effects of CXCL14 expressed by stromal fibroblasts205,277. Laser capture micro-
dissection of matched prostate tumor and non-tumor stroma revealed an upregulation of 
CXCL14 mRNA and protein in CAFs. Engineered fibroblasts overexpressing CXCL14 
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promoted an activated fibroblast-phenotype with enhanced proliferation and migration. 
CXCL14-fibroblasts also enhanced proliferation and migration of LNCaP prostate cancer cell 
in vitro through paracrine effects involving CXCL14-induced factors. Tumor progression was 
stimulated by CXCL14-fibroblasts through multiple mechanisms, including autocrine effects 
on the fibroblasts and paracrine stimulation of macrophage infiltration and angiogenesis, 
without any change in the epithelial-stroma ratio (Figure 5). An increase in NK-cells, as 
demonstrated in other tumor models, was not detected in this study205.  
 
Figure 5: Tumor promoting effects of CXCL14-expressing fibroblasts.  
Figure adapted from205. 
As CXCL12, CXCL14 is also defined as an ELR- chemokine and has, as previously 
mentioned, been demonstrated to exert inhibitory effects on blood vessel formation. 
However, this study showed that tumors with CXCL14-overexpressing fibroblasts had an 
increase in CD31-positive blood vessel compared to control tumors, associated with 
increased levels of FGF-2 released from the fibroblasts. These blood vessels also exhibited a 
reduction of pericyte coverage205. Another study on breast cancer demonstrated migratory 
and invasive features of stroma-derived CXCL14277. Together, these studies suggest 
protumoral effects of CXCL14 expressed in the tumor stroma across cancer types. 
Tumor promoting functions of cancer cell-derived CXCL14 has also been reported. CXCL14 
expression was mainly localized to the invasive front of pancreas and colorectal tumors, and 
the chemokine was also shown to enhance the invasive capacity of cancer cells in vitro 
308,317,318. Preliminary findings of E-cadherin downregulation and MMP9 induction in 
pancreatic cancer cell lines, subsequent to CXCL14 stimulation, have been suggested as an 
underlying mechanism for the enhanced invasion308. Similar findings on altered motility and 
invasion was found in breast cancer cells through a reactive oxygen species (ROS)-mediated 
upregulation of CXCL14. Enhanced ROS levels in breast cancer cells augmented CXCL14 
expression and promoted migration, invasion, tumor and metastasis formation in vivo. ROS 
activation of the transcription factor AP1 was shown to bind the CXCL14 promoter and 
enhance Ca2+ levels in the cytoplasm by interacting with the inositol 1,4,5 triphosphate. These 
data reveal a novel activation of an AP1-CXCL14-calcium pathway activated by oxidative 
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stress in breast cancer that promotes tumor cell migration, invasion and metastasis317. In line 
with this study, another report showed effects of CXCL14 on metastasis formation of 
osteosarcoma cells in vivo319.  
Organ-specific tropism of metastasis has also been linked to CXCL14. A study by Takiguchi 
et al. showed that CXCL14 was specifically involved in bone tropism of lung cancer cells. A 
bone-seeking subclone of lung cancer cells upregulated 72 genes, among which CXCL14 was 
one of the most induced. Knock down of CXCL14 in the bone-metastatic subclone prior to 
intracardial injection slightly reduced metastasis to the bone and interestingly, increased 
metastasis to the adrenal gland. Of note, IHC stainings of CXCL14 in CXCL14-silenced 
tumors showed stromal expression of the ligand, that could possibly also enhance formation 
of bone metastasis and might explain the non-complete blockade of bone metastasis 
following CXCL14-downregulation. Furthermore, CXCL14 was highly expressed in bone 
metastasis from human lung cancer patients, both in the tumor cells and in the bone 
microenvironment320.  
Another study also demonstrated CXCL14 expression to be elevated in CAFs in ER negative 
and triple negative breast cancer patients. In addition, CXCL14 was highly expressed in bone 
metastasis compared to metastasis in lung liver and brain. These correlative data thus suggest 
that CXCL14 expressed by CAFs in primary tumors also could be important for bone 
metastatic tropism of tumor cells in certain breast cancer patients212. 
5.2.3 CXCL14 expression and cancer patient prognosis 
Only few studies have so far investigated the potential prognostic value of CXCL14 
expression in cancer. Some of these analyses demonstrated a correlation between high 
CXCL14 protein levels and a more favorable prognosis, whereas others showed that 
CXCL14 was associated with impaired survival311,321,322.  
The CXCL14 gene was included in two gene expression signatures that predicted worse 
disease free survival of prostate and ovarian cancer, respectively 321,322. In addition, CXCL14 
was part of a gene expression signature that correlated with the presence of metastasis in 
breast cancer patients323. Elevated CXCL14 transcripts have also been demonstrated in 
papillary thyroid carcinoma (PTC) to significantly associate with lymph node metastasis324.  
Analyses of CXCL14 protein levels have also revealed a correlation to cancer survival in 
several reports. CXCL14 was shown to predict decreased overall survival in osteosarcoma 
patients and autocrine CXCL14/NFκB-signaling was induced by hypometylation of the gene 
encoding the transcription factor Iroquois homeobox1 (IRX1). In addition, higher levels of 
CXCL14 were found in patients with lung metastasis, compared to patients without319. 
Consistently, Zeng et al. showed that an upregulation of CXCL14 in colorectal cancer 
patients was associated with tumor-node metastasis (TNM) stage, differentiation grade and 
tumor size, and correlated with disease recurrence and shorter overall survival318.  
Other studies have instead reported on associations between high CXCL14 protein expression 
and good prognosis in breast and colorectal cancer311,325. Notably, none of these studies have 
considered the cell type responsible for CXCL14 expression and addressed the possibility 
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that the prognostic impact of CXCL14 may be determined by the tumor compartment in 
which CXCL14 is produced. 
5.2.4 CXCL14 as an inducer of a protumoral CAF-phenotype 
Tumor-stimulatory abilities and higher proliferative rates characterize CAFs, as compared to 
normal fibroblasts326,327. As previously discussed, CXCL14 promoted NIH-3T3 fibroblast 
proliferation and migration. CXCL14-fibroblasts where also more potent in enhancing 
xenograft tumor growth compared to control fibroblasts, suggesting that CXCL14 could be 
involved in determining a specific tumor promoting CAF-phenotype205. 
As mentioned previously, expression of the transcription factor twist in CAFs enhanced 
protumoral effects of fibroblasts. Interestingly, in the study by Sung et al. a Twist-induced 
CAF-phenotype exhibited increased expression of CXCL14 and FSP-1184, further supporting 
expression of CXCL14 in a previously defined CAF-subset179. In addition, during liver injury 
hepatic stellate cells become ECM-producing myofibroblasts, with some phenotypes similar 
to CAFs. Interestingly, CXCL14 was identified as a novel gene specifically upregulated in 
these hepatic stellate cells upon activation328. 
Together, these studies indicate that CXCL14 could be a potential marker of a particularly 
aggressive CAF-subset, a suggestion that need further experimental validation. 
5.2.5 CXCL14, an orphan chemokine 
Since the receptor for CXCL14 is currently unknown, the downstream signaling of the 
chemokine is poorly characterized. Calcium influx and activation of NFκB and ERK have 
been demonstrated as intracellular signaling events of CXCL14205,329.  
The conflicting data on the role of CXCL14 in tumor biology might be explained by the 
different settings and models used in the different studies, which might display variable 
expression of the unidentified receptor(s) and tissue- or cell-type-specific signaling. Tumors 
in which CXCL14 stimulates growth might be characterized by a stromal-specific expression 
of a CXCL14 receptor. The interaction with CXCL14 could activate fibroblasts and induce 
secretion of tumor promoting factors that enhances tumor progression. On the other hand, 
tumors in which CXCL14 is growth-inhibitory might display preferential expression of the 
receptor on the malignant cells. 
Although no signaling receptor has been discovered, CXCL14 has been demonstrated to bind 
CXCR4 and function as an inhibitor of CXCR4-CXCL12 signaling330. However, a recent 
study showed that CXCL14 did not affect CXCR4 mediated calcium mobilization, MAPK 
signaling or CXCR4 internalization331. This suggests that the functional interaction of the 
CXCL12 and CXCL14-pathways depend on a yet unidentified receptor and could possibly 
involve heterodimerization of CXCR4 and this receptor. 
An improved understanding of normal functions and roles in tumor biology of CXCL14, as 
well as rational targeting, is obviously dependent on identification of critical signaling cell 
surface receptors.  
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6 PRESENT INVESTIGATION 
6.1 AIMS 
The general aim of this thesis was to understand the functional roles of the chemokine 
CXCL14, produced by cancer-associated fibroblasts, in tumor progression and metastasis 
formation of prostate- and breast cancer, and to investigate the potential clinical relevance of 
CXCL14. Specific aims were: 
• To investigate the molecular cell signaling mechanisms underlying the protumoral 
functions of CXCL14-expressing CAFs 
• To explore the prognostic significance of CXCL14 expression in breast cancer 
• To explore potential pro-metastatic effects of CXCL14 produced by CAFs 
• Identify a receptor for CXCL14 
 
6.2 RESULTS AND DISCUSSION 
6.2.1 Paper I 
Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide 
signaling for their tumor-supporting properties 
Cancer-associated fibroblasts are the most abundant cell type within the tumor 
microenvironment and they stimulate tumor growth, progression and metastasis through 
paracrine interactions with cancer cells or other stromal cells. The existence of CAF-
phenotypes with different abilities to promote or inhibit tumor progression has recently been 
highlighted. CAF-phenotypes could potentially be identified by distinct markers and secreted 
proteins. Various secreted factors, including chemokines, have also been identified to 
promote tumor progression and metastasis.  The chemokine CXCL14 was previously 
identified as a CAF-secreted factor that enhanced prostate tumor growth via multiple 
mechanisms, including autocrine effects on fibroblasts, and paracrine effects on angiogenesis 
and macrophage infiltration. In this study, the mechanisms of the protumoral effects 
CXCL14-expressing fibroblasts were explored and how the tumor promoting features of 
these CAFs are maintained.  
We identified nitric oxide synthase 1 (NOS1) as a novel component of CXCL14-intracellular 
signaling in CAFs important for their tumor promoting functions. Gene expression analysis 
of engineered fibroblasts with a stable CXCL14 expression (CXCL14-fibroblasts) revealed 
an upregulation of the enzyme NOS1, compared to control fibroblasts. The upregulation was 
induced by enhanced oxidative stress in CXCL14-fibroblasts and the increased NO levels 
where used in intracellular processes to enhance CAF-tumorigenic functions. This was 
evident by enhanced protein nitration but no increase in NO-secretion by CXCL14-
fibroblasts. 
Both genetic and pharmacological inhibition of NOS1 demonstrated a reduction of CXCL14-
fibroblast proliferation and migration. Specific downregulation of NOS1 in CXCL14-
fibroblasts, prior to co-injection with prostate tumor cells for the formation of xenograft 
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tumors in SCID mice, showed that the CXCL14-fibroblast-mediated increase in tumor 
growth and macrophage infiltration was dependent on NOS1. To answer the question if the 
NOS1-dependency remained across tumor types, the functions of CXCL14-fibroblasts were 
also investigated in a xenograft model of breast cancer. Co-injection of CXCL14-fibroblasts 
and MCF7 breast cancer cells significantly enhanced tumor growth, angiogenesis and 
macrophage infiltration, similar to the result obtained with the prostate tumor model. 
Downregulation of NOS1 in this model also reduced xenograft tumor growth and 
macrophage infiltration. Moreover, increased lymph angiogenesis was discovered as a novel 
protumoral function of CXCL14-expressing CAFs in both the breast and prostate tumor 
model. 
In summary, these results show that the tumor promoting functions of CXCL14-fibroblasts 
are maintained by expression of NOS1. Targeting of the NOS1/NO signaling pathway in 
CXCL14-expressing CAF-subsets should be explored as a treatment intervention for breast 
and prostate cancer. Our study also encourages future exploration of the involvement of 
NOS1 in the downstream intracellular signaling of other chemokines. 
6.2.2 Paper II 
Expression of the chemokine CXCL14 in the tumor stroma is an independent marker of 
survival in breast cancer 
CXCL14 is a chemokine with elevated expression in the tumor stroma of breast and prostate 
cancer. CXCL14 derived from cancer-associated fibroblasts have previously shown tumor 
promoting effects in mouse models of prostate and breast cancer. Earlier studies have 
demonstrated contradictory results on the role of CXCL14 in cancer progression and the 
clinical relevance of CXCL14. This could be explained by cell type-specific expression of 
CXCL14 or the unidentified receptor. In this study we investigated the clinical relevance and 
prognostic significance of compartment-specific expression of CXCL14 in a breast cancer 
cohort of 498 patients. 
RNAscope analyses of CXCL14 mRNA expression revealed that breast cancer tissue display 
variable expression both in the tumor cells and in the tumor stroma. Associations of CXCL14 
expression with clinicopathological parameters showed that epithelial CXCL14 expression 
was significantly associated with ERα positivity and low proliferation. On the contrary, 
stromal CXCL14 expression did not associate with any of the established clinicopathological 
parameters or subtypes of breast cancer. Notably, survival analysis identified CXCL14 
expression in the tumor stroma as an independent marker of poor prognosis in breast cancer. 
High stromal, but not epithelial, levels of CXCL14 mRNA correlated significantly with 
shorter recurrence-free and breast cancer-specific survival in both uni- and multivariable 
analyses. Sub-set analyses showed that the correlation of stromal CXCL14 expression and 
worse clinical outcome was particularly prominent in patients of the ERα negative-, triple 
negative and basal subgroups, suggesting particular relevance for stromal CXCL14 in the 
progression of breast cancers belonging to these subgroups. 
The finding of CXCL14 as a stromal prognostic marker adds to a number of recent studies 
identifying prognostic significance of stroma-expressed proteins, and stromal-gene-
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signatures. Furthermore, novel clinical relevance of a stroma-derived secreted factor is here 
demonstrated. Based on the prognostic significance in difficult-to-treat subgroups of breast 
cancer, CXCL14 should also be considered as a candidate drug target. These results also 
encourage additional experimental studies to explore the mechanism behind the poor 
survival-associations, including paracrine effects of CXCL14 on tumor cells and studies on 
identification of a receptor for CXCL14. 
6.2.3 Paper III 
A novel ACKR2-dependent role of CAF-derived CXCL14 in epithelial-to-mesenchymal 
transition and metastasis of breast cancer  
CAF-derived CXCL14 is an orphan chemokine that previously was shown to enhance 
prostate and breast tumor growth in vivo through NOS1 dependent mechanisms, and to 
associate with shorter survival of breast cancer patients. The underlying mechanisms of the 
poor-prognosis association of CXCL14 are not known. In this study we therefore explored 
the involvement of CAF-derived CXCL14 in tumor cell EMT, invasion and metastasis in 
tissue culture- and mice models and in patient gene expression datasets of breast cancer. To 
better understand the biological effects and tumor promoting activities of CXCL14 we also 
aimed to identify a receptor for the orphan chemokine. 
CAF-derived CXCL14 was shown to promote formation of lung metastasis in SCID mice. 
Subsequent to tail-vein injection, metastasis was enhanced by “priming” of breast cancer cells 
in vitro with CXCL14-fibroblasts or by forced expression of CXCL14 in cancer cells. 
Mechanistic understanding of the pro-metastatic effects was provided by tissue culture- and 
xenograft models of breast cancer. Co-culture of breast cancer cells with CXCL14-fibroblast 
stimulated EMT, tumor cell migration and invasion. These could be directly mediated by 
recombinant CXCL14 but might also involve CXCL14 induced factors. The loss of epithelial 
markers and increase in mesenchymal markers and EMT transcription factors were also 
shown in a xenograft model of breast cancer where cancer cells were co-injected together 
with CXCL14-overexpressing fibroblasts. 
In an effort to find a CXCL14-receptor, initial experiments were performed with pertussis 
toxin. These indicated that CXCL14, like other chemokines, signals through a member of the 
Gαi subfamily of GPCRs. Knock down of several CXCL14 receptor candidates demonstrated 
that the atypical G-protein coupled receptor (GPCR) ACKR2 mediated CXCL14-induced 
molecular signaling, including ERK phosphorylation and enhanced NOS1, and cellular 
responses, including fibroblast proliferation and breast cancer cell EMT, migration and 
invasion.  
Clinical relevance of the experimental findings was demonstrated by correlations of the 
CXCL14 transcript with an EMT gene expression signature in different breast cancer gene 
expression data sets. The correlation was less prominent in patients of the Basal, HER2 and 
Luminal A subgroup with low ACKR2 expression, further supporting the role of ACKR2 as a 
novel CXCL14 receptor.  
Altogether, these findings describe the first signaling receptor for CXCL14 and recognize 
previous unknown abilities of ACKRs to function as active transducers of chemokine 
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signaling. We also identify a novel clinically relevant role for CXCL14/ACKR2 signaling in 
inducing tumor cell EMT and invasion, important for formation of metastasis. The recent 
finding that stromal, but not epithelial expression, of CXCL14 is associated with shorter 
survival in breast cancer suggests that the paracrine stromal-epithelial CXCL14/ACKR2-
signaling is most clinical relevant. Compartment-specific analyses of potential impact of 
ACKR2 have not been investigated but are prompted by the findings of the present study. 
Targeting of the CXCL14/ACKR2 pathway for treatment of breast cancer patients with a 
high stromal expression of CXCL14 should be explored in future studies. In addition, future 
studies should also consider the relevance of this pathway in other tumor types. 
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7 GENERAL OUTLOOK 
Metastatic disease is the major cause of cancer death and there is no current treatment that 
efficiently cures patients with metastasis. Inhibition of the metastatic process poses an 
attractive strategy to improve cancer patient survival. For efficient inhibition of metastasis 
formation it is crucial to understand the underlying steps. Reactivation of developmental 
programs and the interplay between tumor cells and the microenvironment have been 
demonstrated to affect the metastatic cascade. 
As described in this thesis, the reversible EMT/MET process -a program highly dependent on 
activation-signals from the tumor microenvironment- is relevant for the individual steps of 
metastasis formation. This developmental program constitutes a plausible target for treatment 
of metastatic disease. EMT might however be difficult to target due to the reversible process 
of MET that results in increased outgrowth of cancer cells at distant sites. One way to 
approach this problem is to identify EMT- and MET-mediators and to target these pathways 
individually or simultaneously. Studies on the regulators of EMT/MET are therefore highly 
warranted. In paper III we identified CXCL14/ACKR2 signaling to induce EMT, invasion 
and metastasis. Targeting EMT-inducing factors, such as CXCL14 or ACKR2, would be an 
option for metastasis prevention. 
Also, tumor cells can remain dormant for years in recipient tissues before outgrowth is 
initiated. The ability of tumor cells to escape tumor dormancy depends partly on signals from 
the recipient tissue microenvironment. What are the microenvironmental factors that keep 
tumor cells in a dormant state, or alternatively activate them for proliferation and outgrowth? 
Since an inability of the EMT to MET transition can underlie dormancy, inhibition of stroma-
produced inducers of MET appears as an interesting therapeutic opportunity.  
To gain further mechanistic insight of which microenvironmental cues that allow only a 
minor number of cancer cells to undergo the different steps of metastasis and form secondary 
tumors is highly warranted. This thesis discusses the functions of chemokines, produced for 
example by stromal fibroblasts, in regulating metastasis formation. Chemokines enhance 
EMT and invasion of cancer cells in the primary tumor. In addition, expression of 
chemokines in the metastatic niche determines organotropism by directing spread of tumor 
cells to these organs. By interfering with certain chemokine-signaling pathways a dual 
targeting of metastasis formation could be obtained. Both dissemination of tumor cells, as a 
result of EMT and invasion, and the tissue colonization from early-disseminated tumor cells 
would be prevented. However, the involvement of CXCL14 in dictating organtropism to 
certain organs remains unknown. As reported in this thesis CXCL14 show high expression in 
brain, lungs and bone, which would suggest a preference for ACKR2 positive tumor cells to 
seed in these organs more efficiently than in other organs. Future studies should aim to 
explore this. 
Besides effects of CXCL14 on tumor cells, the chemokine also plays a major role in 
enhancing CAF-tumor-promoting capabilities. In paper I we demonstrate that CXCL14-
expressing CAFs promote tumor progression by upregulation of NOS1/NO signaling. The 
clinical importance for the role of CXCL14 in the stroma was demonstrated in paper II, and 
stromal expression was identified as a prognostic marker in breast cancer patients. The 
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studies in this thesis have revealed several candidate drug targets, whose targeting would 
interfere with the pro-tumoral effects of CAFs. These include CXCL14 itself, its receptor 
ACKR2 and components of the NOS1/NO signaling pathway.  
Recent studies about transcriptional programs regulating CAF-phenotypes have shown the 
importance of EMT transcription factors, as discussed in this thesis. This indicates an 
involvement of EMT transcription factors -as well as other developmentally important 
transcription factors- in CAF-activation, and possibly determining different CAF-subsets. 
Thus, EMT-stimulating factors should be explored as mediators of CAF-heterogeneity. The 
identified function of CXCL14 in both enhancing tumor cell EMT and activating CAF-
characteristics also supports this hypothesis, but further studies are needed. 
The context-dependent pro- or anti-tumoral roles of CXCL14 during tumor progression 
should also be further analyzed to elucidate the underlying mechanism(s). We believe that 
cell type-specific expression of CXCL14 and its receptor could be one explanation. The 
identification of ACKR2 as a CXCL14-receptor will facilitate such studies and thereby 
significantly improve the possibilities of a more in-depth understanding of CXCL14 function 
in tumor biology. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Cancer är ett samlingsnamn på flera sjukdomar som uppstår som en konsekvens av 
förändringar i våra gener. Dessa genförändringar bildas i flera steg över lång tid och har 
framförallt visat sig vara orsakade av livsstilsfaktorer. Det finns även ett fåtal genetiska 
förändringar som är nedärvda och när så är fallet talar man om ärftlig cancer. Vilken typ av 
cancer man drabbas av beror på i vilken vävnad och celltyp som de genetiska förändringarna 
har uppstått. Bröst- och prostata cancer hör till de vanligaste cancerformerna. 9000 kvinnor 
drabbas årligen av bröstcancer i Sverige och ungefär lika många män drabbas av 
prostatacancer.  
Normalt bildas det kontinuerligt nya celler i alla kroppens vävnader genom kontrollerade 
celldelningar. När en cell har erhållit genetiska förändringar stängs dessa kontrollprogram av 
och celldelningen kommer i obalans. Gener som driver på tillväxt får en ökad aktivitet medan 
gener som bromsar tillväxt får en minskad. Trots att cancer består av många olika sjukdomar 
har cancerceller från olika cancerformer vissa gemensamma karaktärsdrag. De producerar 
sina egna tillväxtfaktorer och är okänsliga mot tillväxthämmande signaler. De har 
motståndskraft mot att dö och istället en förmåga att dela sig i oändlighet. Cellerna växer på 
varandra och bildar så småningom en klump, en tumör. Denna tumör fortsätter att växa och 
cancerceller stimulerar blodkärlsbildning som gör att tumören förses med syre och 
tillväxtfaktorer, så att den kan växa sig ännu större. Ytterligare ett karaktärsdrag är att 
cancerceller har en ökad förmåga att flytta på sig och invadera in i omkringliggande vävnader 
och in i blod- eller lymfkärl. Väl inne i blodet färdas de genom kroppen och kan ta sig vidare 
in i nya organ, där de kan bilda tumörer på nytt, så kallade dottertumörer eller metastaser.  
Tumörer består inte enbart av cancerceller utan även av andra celltyper och molekyler, det så 
kallade tumörstromat, som kommunicerar med cancercellerna för att stimulera tumörtillväxt 
ytterligare. En av de vanligaste celltyperna i stromat är cancer-associerade fibroblaster som 
påverkar tumörens tillväxt, utveckling och metastasering genom ett samspel med cancerceller 
och andra stromala celler. Detta samspel äger rum genom utsöndring av signalmolekyler, 
vilka binder till specifika målmolekyler, receptorer, på mottagarcellerna. 
En sådan signalmolekyl är CXCL14 som produceras av fibroblaster i tumörstromat i bröst 
och prostatacancer. Fibroblast-deriverat CXCL14 är viktigt för tillväxt av både bröst- och 
prostatacancerceller i experimentella modeller. CXCL14 kan även förändra tumörcellerna så 
att de blir mer migratoriska och invarderar närliggande vävnader, samt ökar metastasering. 
Den receptor som CXCL14 binder till på cancercellerna har tidigare varit okänd. Vi har 
identifierat en receptor, ACKR2, som är involverad i CXCL14s biologiska effekter. Genom 
att experimentellt ”ta bort” denna receptor minskas cancercellernas intracellulära signaliering, 
migration och invasion. Vi har även lyckats identifiera en annan tumörstimulatiorisk molekyl, 
NOS1 som induceras av CXCL14. I prover från bröstcancerpatienter har vi också visat att 
stromalt CXCL14 är kopplat till sämre överlevnad och stromalt CXCL14 identifierades som 
en prognostisk markör.  Genom att antingen utveckla läkemedel riktade mot CXCL14 själv, 
dess receptor ACKR2 eller NOS1-signalering tror vi att utvecklingen av prostata- och 
bröstcancer skulle kunna hämmas. Det behövs emellertid prövas i framtida studier om så är 
fallet.  
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